mddt_10k.htm

0001640334-17-001275.txt : 20170619 0001640334-17-001275.hdr.sgml : 20170619 20170619154807 ACCESSION NUMBER: 0001640334-17-001275 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170619 DATE AS OF CHANGE: 20170619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medico International Inc. CENTRAL INDEX KEY: 0001658432 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 371793037 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-208050 FILM NUMBER: 17918473 BUSINESS ADDRESS: STREET 1: 187 E. WARM SPRINGS ROAD STREET 2: SUITE B273 CITY: LAS VEGAS STATE: NV ZIP: 89119 BUSINESS PHONE: (732) 383-9118 MAIL ADDRESS: STREET 1: 187 E. WARM SPRINGS ROAD STREET 2: SUITE B273 CITY: LAS VEGAS STATE: NV ZIP: 89119 10-K 1 mddt_10k.htm FORM 10-K mddt_10k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

x Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 2016

o Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission file number 333-208050

MEDICO INTERNATIONAL INC.

(Exact name of small business issuer as specified in its charter)

Nevada

8052

37-1793037

(State or other jurisdiction
of incorporation or organization)

(Primary Standard Industrial
Classification Number)

(IRS Employer
Identification Number)

187 E. Warm Springs Road, Suite B273

Las Vegas, NV 89119

(Address of principal executive offices)

(732) 383-9118

(Issuer's telephone number)

None

Securities registered under Section 12(b) of the Exchange Act

None

Securities registered under Section 12(g) of the Exchange Act

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes ¨ No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer   ¨

Accelerated filer   ¨

Non-accelerated filer ¨

Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The aggregate market value of the registrant’s outstanding common stock held by non-affiliates of the registrant computed by reference to the price at which the common stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was $0. The registrant’s common stock has not been traded in the public market.

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 3,697,000 common shares issued and outstanding as of June 12, 2017.

TABLE OF CONTENTS

Page

PART I

Item 1.

Description of Business.

3

Item 1A.

Risk Factors.

9

Item 1B.

Unresolved Staff Comments.

17

Item 2

Description of Property.

18

Item 3.

Legal Proceedings.

18

Item 4.

Mine Safety Disclosures.

18

PART II

Item 5.

Market for Common Equity and Related Stockholder Matters.

19

Item 6.

Selected Financial Data.

20

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

20

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

23

Item 8.

Financial Statements and Supplementary Data.

24

Item 9.

Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.

34

Item 9A.

Controls and Procedures

34

Item 9B.

Other Information.

35

PART III

Item 10

Directors, Executive Officers, Promoters and Control Persons of the Company.

36

Item 11.

Executive Compensation.

37

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

38

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

39

Item 14.

Principal Accounting Fees and Services.

39

PART IV

Item 15.

Exhibits

40

Signatures

PART I

Item 1. Description of Business

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements. These statements relate to future events or our future financial performance. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

Medico International Inc. (the “Company”) was incorporated in the State of Nevada on September 18, 2015. The Company’s registration statement on Form S-1 was declared effective by the Securities and Exchange Commission on December 22, 2015.

The Company was formed and organized for the purposes of acting as the holding company for Smile More Holding Pte. Ltd., which is a private Singapore corporation (referred to herein as “Smile Central”). Smile Central is a dental company employing the latest techniques in oral care and oral surgery in Singapore. Formed in 2014, Smile Central has expanded to 5 locations in population-dense high foot traffic residential centers all over Singapore.

Smile Central's business objectives are to improve techniques and achieve the following:

- make the existing treatment more effective;

- decrease the recovery time of patients; and

- reduce the cost of innovative/cutting edge dental procedures.

Smile Central is designed to enhance this market with its small core of eminent dentists, key employees, and strong outsourced partners. Management believes that Smile Central has a business model that is easily scalable to effect rapid growth and expansion.

3

Table of Contents

Recent Developments

Due to the continued consolidated losses experience by the Company as the result of the losses of the Company’s wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), which included $232,769 for the fiscal year ended December 31, 2015, $801,760 for the fiscal year ended December 31, 2106, the Board of Directors of the Company believed it was in the best interests of the Company and its shareholders to dispose of Smile Central. In addition, the Company had provided Smile Central with over $600,000 in intra-company loans (the “Intra-Company Loan”).

The Company’s former majority shareholders, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. (the “Majority Shareholders”), became shareholders of the Company in 2015 by exchanging all of the outstanding share capital of Smile Central (“Smile Shares”) for 3,000,000 shares of the Company’s common stock (the “Medico Shares”) and the Majority Shareholders desired to re-acquire the Smile Shares.

On June 5, 2017, the Company closed the transactions under the Share Exchange Agreement (“ Share Exchange Agreement”) by and between the Company, Eminent Healthcare Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company, for the sale of all of the issued and outstanding ordinary shares of the Company’s 100% wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (the “Stock Purchase”). Prior to the closing of the Stock Purchase, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. were the Company’s majority shareholders. Liew Min Hin, the Company’s former Chief Financial Officer and former member of the Board of Directors, owns 100% of Eminent Healthcare Pte. Ltd., and is the father of Dr. Daniel Liew, the Company’s former Chief Executive Officer and former member of the Board of Directors.

Pursuant to the Share Exchange Agreement, in consideration for transferring the Smile Shares to the Majority Shareholders and waiving the Intra-Company Loan, the Company received all of the rights, interests, claim and title in that certain US patent known as “Method for diagnosing malignancy in pelvic tumors”, US Patent No. 6,112,108 (the “Patent”), which Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”) had the right and ability to deliver to the Company and in connection with the closing of the Share Exchange Agreement, Jiang Chun Yan was appointed as the CEO and sole member of the Company’s Board of Directors.

In addition, under the Share Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG.

The effect of the transactions set forth in the Share Exchange Agreement is that commencing June 5, 2017 the Company will no longer own and operate dental clinics in Singapore but will focus its efforts in the area of cancer diagnostics tools in connection with the Patent.

The below information pertains to the operations of Smile Central.

The Company

Through 2016 Smile Central operated 5 dental clinics throughout Singapore, with each clinic meeting its respective revenue and profit targets every quarter so far. Since 2015, Smile Central has expanded its operations by adding a new dental center adjacent to its Aljunied clinic and increasing the number of dental operating chairs at its Jurong location from two (2) to six (6). The facilities for the new dental center in Aljunied have been leased and equipment has been purchased. Smile Central is currently completing renovations to the facilities. Its business model focuses on recruiting qualified and experienced dentists, supported by well-trained clinic support staff. Our dentists have post-graduate training in the fields of endodontics, orthodontics, periodontics, prosthodontics, paedodontics, oral surgery and implant dentistry. Hence, we are able to carry out procedures ranging from the routine cleaning and filling to the most complex ones involving aesthetics and surgery.

In addition to basic dental care, our strengths include:

· Invisible braces for the young and for working adults.

· Dental implants to rehabilitate functionality.

Smile Central positions itself as an affordable dental chain where patients of all demographics can afford basic and complex dental care with government Medisave claims and government-aided subsidies like the Community Health Assist Scheme and the Pioneer Generation subsidy for the elderly.

Planned Services (In Addition to Current List of Services)

4

Table of Contents

Among some of the new techniques and procedures Smile Central is looking to incorporate are:

· Laser Teeth Whitening

· Aesthetic Implants and Implant Maintenance

· Laser Surgery - used to perform soft-tissue surgery, including removing tumors and lesions from the soft tissues of the mouth, as well as tooth cleaning and plaque removal

· Oral and Maxillofacial surgery - the treatment of many diseases, injuries and defects in the head, neck, face, jaws and the hard and soft tissues of the Oral (mouth) and Maxillofacial (jaws and face) region.

Goals for Expansion

According to the Singapore Dental Council, the current dentist-to-population ratio in Singapore is 1:2,960, a ratio we feel is indicative of the scope of expansion possible for the dental industry. In comparison, for 2013-2014, the statistics for the dentist-population ratio in England is around 1:2,000, with some areas having as high a ratio as 1:1,682. We feel that due to the highly-fragmented dental market in Singapore, the market has room to grow by another 40-50%, with 15% yearly gains possible for at least the next 5 years. Management is currently in talks with graduate dentists from overseas (predominantly from the UK and Australia) to employ them to staff the new locations. As is the current practice, each location will be overseen by a senior partner who is also a practicing specialist. Management hopes to staff each new location initially with 3 dentists working under the senior specialist. Leveraging on the existing expertise and business partnerships with suppliers, the new locations will be set up in the most cost-efficient manner in order to capitalize on the current opportunities immediately.

Management also currently has in place a program of sending selected high-performing dentists under its employment to increase their knowledge and expertise through seminars, courses, further study and specialization. This is in line with its policy of training the dentists to assume senior partner positions at new locations.

Direct Competition

The direct competitors of Smile Central are the dental companies with 3-10 clinics in their stable. Smile Central is already leveraging on economies of scale to provide a more professional and comfortable experience for patients at a lower cost, and should see off competition from the individual standalone clinics. The increased suite of services at the new locations should position it above ordinary clinic chains as it is able to provide a well-rounded range of services.

5

Table of Contents

Future Competition

Future competition will come in the form of new clinic chains who consolidate to grow, or chains which acquire standalone clinics to increase their size. Management feels that with constant learning and innovation, Smile Central will be able to stay ahead of the competition by offering continually advanced and modern services and equipment at a competitive price point.

Competitive Analysis

Overall, management contends that the Company competes by being a leading provider of a full line of technologically advanced procedures and techniques, supported by the exceptional core managerial team and the able dentists and staff. One of the primary areas of competition is for diligent and conscientious dentists who are personable and able to form good client-doctor relations. There is also strong competition for more senior dentists with their own clientele.

With our many opportunities for continuing education learning, we believe we will be able to attract young dentists with a view to a long career in the company. Dentists with good PR skills should also be identified and recruited.

Target Market Profile

Smile Central is rolling out a plan to target different segments of the market.

·

We actively recruit dentists who are good with kids and who are parents themselves, to cater to the pediatric dental market. Frequently the parents of the kids also come in for treatment when we attend to their kids.

·

We target the young professionals who want a comfortable space to have their dental treatment.

·

Our dentists take care of the senior citizens by educating them on oral hygiene and providing subsidized oral care.

·

There is ethnic diversity in our dentists and staff - they hail from different ethnic groups and are multilingual so as to cater to every segment of the market.

Future Markets

Smile Central plans to build its Singapore network of clinics until it perceives that the Singapore market is saturated. Following that, Smile Central will look to the neighboring countries for expansion, as it believes the level of dental care is lacking in the developing countries around Singapore.

At the same time, moving more towards dental surgery and aesthetics will see the revenues increase as these treatments are more expensive, with some aesthetic surgery going up to $40,000 per patient. 3D Radiography is another segment management is looking to go into - in 3D Radiography, a large volumetric 3D image is created in a single 14 second 3D scan that provides the highest resolution with the lowest radiation dose. This is safer and more comprehensive than traditional radiography, and as the population becomes more savvy and affluent, more would turn towards this rather than traditional radiography.

Governmental Approvals

Smile Central operates within a very strict governmental approval framework and all treatment methods and procedures are completely compliant with governmental laws and guidelines.

6

Table of Contents

Demographics

Singapore’s dental services and equipment and supplies market is expected to grow in tandem with the city state’s reputation as the region’s healthcare hub and center of healthcare excellence. Singapore is ranked sixth out of 191 countries globally and the best in Asia by the World Health Organization.

As a multi-faceted medical hub, Singapore attracts a growing number of medical professionals and multi-national healthcare-related companies from various parts of the world to share and exchange their expertise, conduct healthcare-related research and training as well as host international conferences and events.

With Singapore's well-developed infrastructure and robust medical ecosystem, healthcare providers in Singapore are constantly strengthening their medical capabilities through professional exchanges and access to innovation in medical technology.

In Singapore, medical travelers can receive quality medical care in an environment that is safe and welcoming, with no uncertainties from political instability, social unrest, or worries about poor health safety. This is on top of an efficient transportation system, wide range of accommodation options, and a wide variety of leisure offerings to enhance the experience in Singapore.

Singapore's quality healthcare, as one of the best in the world, is internationally recognized.

·

Ranked first for most efficient healthcare system, out of 51 countries, in 2014 by Bloomberg.

·

Ranked second in the world for health-care outcomes according to The Economist Intelligence Unit (EIU) in 2014.

·

Ranked first as a global favorite medical tourism destination in PHD Chamber Medical and Wellness Tourism Report 2013.

·

21 hospitals and medical centres and medical organizations in Singapore have obtained the Joint Commission International (JCI) accreditation.

·

Singapore's blood supply ranks among the safest in the world. Blood Services Group HSA (previously known as Singapore's Centre for Transfusion) was appointed a World Health Organization (WHO) Collaborating Blood Centre for Transfusion Medicine for the Western Pacific Region in 1992.

Singapore's increased emphasis on medical tourism has seen the number of tourists traveling to Singapore for healthcare purposes grow significantly. The total medical tourism receipts came in at $832 million in 2013, up from $383 million in 2004, and Singapore's medical tourism market is expected to grow 8.3% per annum from now to 2018.

Singapore’s dental practitioners have seen a steady demand for more complex and specialty dental procedures from foreign visitors who also come here for medical consultation. The country continues to strive to provide first class healthcare systems and facilities to its residents and the international patient market.

The medical and dental sector is also expected to see gains due to the increasing population. The population of Singapore is now 5.4 million, and this is expected to rise to 6.9 million in 2030.

7

Table of Contents

Market Demand

The general status of dental and oral hygiene of Singaporeans is good. Attributing to this success is the Singapore government’s fluoridation of potable water initiative since 1958 and the widespread use of fluoridated toothpaste among the general population. As such, the dental work done by dental practitioners has shifted from the traditional “drill and fill” regime to one that focuses on enhancing the patient’s aesthetic appearance.

The emphasis of the public healthcare service is in preventive dentistry targeted at pupils in schools. Dental care begins with preventive dentistry promoted through the Singapore Health Promotion Board, a statutory board tasked to promote a good and healthy lifestyle among Singaporeans. The Board targets students through a network of 200 static clinics located in schools as well as 30 mobile dental clinics. This plus fluoridation of potable water and availability of fluoridated toothpaste has greatly diminished dental decay and tooth loss.

Singapore provides some of the most advanced dental care in the region. With the third highest GDP per capita income in the world, Singaporeans' demand for the best and most sophisticated dental care is strong. According to a report that highlighted the results of a survey conducted by the Singapore Dental Association, nearly 45% of the population visits the dentist at least twice a year. They spend an average of US$80 for a visit to the dentist.

As an affluent nation, more and more patients are seeking treatment for their children early in the hope of arresting any potential problems with their teeth. More parents are bringing their children to see orthodontists before they lose their baby teeth. Teenagers and adults too are seeking corrective treatments to improve the alignment of their teeth.

Designer and/or transparent braces are popular and appeal to the more aesthetically-conscious and affluent. Costs for such treatments are in the thousands of dollars.

There has also been an increased awareness of oral and dental hygiene. More Singaporeans have adopted a more rigorous approach to oral care by incorporating flossing and gargling with a mouthwash to their typical routine of twice-a-day brushing. Schools have been instrumental in reinforcing this to the children.

Besides serving a more affluent and demanding resident population, dental practitioners have also seen a marked increase in foreign patients seeking dental treatment in Singapore. Wealthy patients from Indonesia, Brunei, Thailand, Malaysia, Philippines, Hong Kong, Cambodia, China and Vietnam began to visit Singapore for medical care in the 1980s. According to a news report, these patients are not looking for a quick clean or check-up, they come for treatments that include cosmetic dentistry that arrest problems of discolored teeth, gaps between teeth, unsightly old crowns and reconstructive work which can cost up to US$60,000.

Singaporean dentists do a lot of overseas teaching and are involved in overseas conferences. They are increasingly seen as experts in their field and are sought after as panelists at dental conferences, to do product demonstrations and as key opinion leaders. According to leading implant suppliers, implants are the fastest growing segment in the global dental market with an annual growth rate of 18-20 percent.

Many dental GPs are improving themselves through workshops and courses and the popular topics include implants and cosmetic dentistry. Cosmetic dentists are now seen as the “plastic surgeons of the dental sector”.

As Singaporean dental practitioners strive to provide more value-added consultations, some are providing their patients more holistic medical care by offering the option for oral cancer screening. Oral cancer is ranked 11th in the list of most common cancers in Singapore, based on information available from the Ministry of Health. Due to the anxiety that may be experienced by patients, this test is conducted selectively only when the patient displays high-risk symptoms and after the dental practitioner provides the appropriate counseling.

8

Table of Contents

Property

Our subsidiary, Smile Central, leases office space for each of our six (6) clinics. The table provided below summarizes the monthly rental cost, before applicable taxes, in Singapore dollars, and the tenancy period for each lease.

Clinic

Rental per mth

Tenancy Period

Aljunied

$

7,000

Aug 2014 – Jul 2017

Aljunied – Dental Lab

$

2,000

May 2015 – May 2017

Jurong

$

34,000

Sep 2015 – Sep 2018

Hougang

$

19,916

May 2015 – May 2018

HougangCentral

$

6,500

Apr 2014 – Apr 2016

SCD Centre

$

20,000

Aug 2016 – Aug 2019

Toa Payoh

$

16,000

Apr 2015 – Mar 2018

Employees

Smile Central employs sixty (60) employees, of which 49 are full-time employees, 11 are part-time employees, 3 full-time doctors (including the Company’s former executive officers, Dr. Liew and Dr. Chew) and 8 contracted doctors.

Item 1A. Risk Factors

We have a history of losses and may never be profitable.

We have an accumulated deficit totaling $(1,161,700), as of December 31, 2016, and we are not profitable. To date our operations have not generated sufficient operating cash flows to pay for the expenses we incur on a current basis. We may not be able to successfully keep or grow our businesses or achieve profitability from our operations in the near future or at all.

Among other things, our ability to achieve sustainable profitability is dependent on:

· Successful marketing and sale of our dental services and plan;

· Our ability to acquire or open additional dental practices and operate them profitably;

· Our ability to develop additional services and plans to serve dentists and their patients.

There can be no assurance that we will achieve sustainable profitability.

9

Table of Contents

Our cash reserves are not sufficient to pay the amounts owing on outstanding obligations.

At December 31, 2016, we had $2,160,082 in current liabilities and working capital deficit of $(1,120,357). We do not have sufficient reserves to pay the amounts owing. As a result, no assurance can be given that the Company will have the resources to repay any or all of its current obligations. The failure of the Company to pay its obligations will have a material adverse effect on the Company, including the possibility of the Company ceasing to conduct operations.

Our net revenue may be adversely affected by changes in the government Medisave program and the Community Health Assist Scheme program or CHAS.

Our clinics are largely dependent upon reimbursements from the Singapore government insurance reimbursement programs known as Medisave and CHAS. The government of Singapore could at any time act to reduce Medisave and/or CHAS reimbursement rates in response to budgetary shortfalls. These reductions would generally be passed on to our practices and negatively affect our revenue and operating results.

Qualification to be able to participate in the Medisave and CHAS reimbursement programs can take up to three (3) months and limits our ability to open new clinics.

Part of our plan to become profitable includes opening additional dental clinics in Singapore. Our ability to quickly open clinics in a desirable location can be hindered by the amount of time that it takes for a new clinic to become qualified by the government to participate in the Medisave and CHAS reimbursement programs, which can take up to three (3) months. This type of delay could give other competing, established dental practices an advantage over us and impede our ability to enter into a given market.

RISKS RELATED TO REGULATORY MATTERS

Our clinics are subject to extensive laws and regulations. If we fail to comply with existing or new laws or regulations, we could suffer civil penalties.

The practice of dentistry is highly regulated. Our operations are subject to extensive laws, regulations, licensing requirements and guidelines set by the Ministry of Health (“MOH”) and the Singapore Dental Council (“SDC”), including regulations pertaining to our operations, the qualifications and conduct of clinical personnel, billing and reimbursement and the privacy and security of protected health information. Although we strive to maintain a legally-compliant business, our operations may not be in compliance with certain laws or regulations, as written or as may be interpreted. Failure to comply with laws and regulations may cause us to incur civil penalties, fines, shutting down of a clinic, or revocation of dentist practicing certificate. This would significantly limit our ability to operate our business. In addition, we could be excluded from participating in the Medisave and CHAS reimbursement programs.

Guidelines set by MOH can be changed at the MOH’s discretion, which could result in significant cost and potentially loss of time to service patients.

Most of our equipment is subject to guidelines set by the MOH regarding minimum requirements, which can change at the MOH’s discretion. In the event that the MOH’s guidelines are revised, we may be required to replace expensive equipment with new equipment, which would represent a significant new expense incurred by each of our clinics. These changes could occur at any time.

Our business operations could be interrupted by problems with our information systems.

Our business is dependent on information systems for operational processes, financial information and our billing operations. Our information system could be vulnerable to damage or interruption from computer viruses, human error, natural disasters, tele-communications failures, intentional acts of vandalism and similar events. A significant or prolonged interruption in our computer network, data center or software applications could have a material adverse effect on our business, financial condition and results of operations.

10

Table of Contents

A catastrophic event may significantly limit our ability to conduct business as normal.

We operate a complex, geographically dispersed business. Disruption or failure of networks or systems, or injury or damage to personnel or physical infrastructure, caused by a natural disaster, public health crisis, terrorism, cyber attack or other catastrophic event may significantly limit our ability and that of the affiliated practices to conduct business as normal, including our ability to communicate and transact with the affiliated practices, as well as with suppliers and vendors, and the ability of the affiliated practices to provide dental care to patients. We are not adequately insured for losses and disruptions caused by catastrophic events, and we may not have a sufficiently comprehensive enterprise-wide disaster recovery plan in place.

RISKS RELATED TO OUR COMMON STOCK

An active trading market for our common stock may not develop, and you may not be able to resell your shares of our common stock at or above the initial public offering price.

Although our common stock has been approved for listing on OTCQB, an active trading market for our shares has not developed and may never develop or be sustained. The initial public offering price of our common stock was arbitrarily determined by our Chief Executive Officer. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell.

The market price for our common stock will likely be volatile because of several factors, including a limited public float.

The market price of our common stock is likely to be highly volatile because there has been no public trading market for our stock. If our stock is approved for trading on the OTCQB, of which there is no guarantee, we will most likely have limited float, which causes trades of small blocks of stock to have a significant impact on our stock price. You may not be able to resell shares of our common stock following periods of volatility because of the market’s adverse reaction to volatility.

Other factors that could cause such volatility may include, among other things:

●

potential investigations, proceedings or litigation that involves or affects us;

●

risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for our planned expansion;

●

actual or anticipated fluctuations in our operating results;

●

overall stock market fluctuations;

●

our ability to raise capital when we require it, and to raise such capital on favorable terms;

●

conditions or trends in the industry;

●

changes in market valuations of other similar companies;

●

announcements by us or our competitors of expansion of clinics;

●

future sales of common stock;

●

actions initiated by the SEC or other regulatory bodies;

●

departure of key personnel or failure to hire key personnel; and

●

general market conditions.

11

Table of Contents

Any of these factors could have a significant and adverse impact on the market price of our common stock. In addition, the stock market in general has at times experienced extreme volatility and rapid decline that has often been unrelated or disproportionate to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock, regardless of our actual operating performance.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.

The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

Even if there is no immediate need for capital, we may choose to issue debt or shares of our common stock in the future and such issuances, if any, could have a dilutive effect on your investment.

We may choose to issue debt or shares of our common stock for investment, acquisition or other business purposes. Even if there is not an immediate need for capital, we may choose to issue securities to sell in public or private equity markets if and when conditions are favorable. Raising funds by issuing securities would dilute the ownership interests of our existing stockholders. Additionally, certain types of equity securities we may issue in the future could have rights, preferences or privileges senior to the rights of existing holders of our common stock.

We cannot assure you that we will declare dividends or have the available cash to make dividend payments, and as a result you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.

Although we do not currently intend to pay dividends, to the extent we decide in the future to pay dividends on our common stock, we will pay such dividends at such times and in such amounts as the board of directors determines appropriate and in accordance with applicable law. Our board of directors may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and implications on the payment of dividends by us to our stockholders or by our subsidiaries to us and such other factors as our board of directors may deem relevant. There can be no assurance that we will pay dividends going forward or as to the amount of such dividends. As a result, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it.

We are a holding company that depends on cash flow from our wholly owned subsidiary to meet our obligations, and any inability of our subsidiary to pay us dividends or make other payments to us when needed could disrupt or have a negative impact on our business.

We are a holding company with no business operations of our own. Our only significant assets are the outstanding capital stock of our subsidiary, Smile Central, which will conduct all of our operations and own all of our operating assets. Accordingly, our ability to pay our obligations is dependent upon dividends and other distributions from our subsidiary to us. The ability of our subsidiary to pay dividends or make other payments or distributions to us will depend on its respective operating results, and the terms of our current and future financing agreements, which may preclude dividends, distributions or other payments.

12

Table of Contents

In addition, because we are a holding company, claims of our security holders will be structurally subordinated to all existing and future liabilities and obligations (whether or not for borrowed money) of our subsidiary. Therefore, in the event of our bankruptcy, liquidation or reorganization, our assets and those of our subsidiary will be able to satisfy the claims of our security holders only after all of our and our subsidiary’s liabilities and obligations have been paid in full.

Anti-takeover provisions under Nevada law could discourage, delay or prevent a change in control of the Company and may affect the trading price of our common stock.

We are a Nevada corporation and the anti-takeover provisions of the Nevada Revised Statutes may discourage, delay or prevent a third party from acquiring our company, even if doing so may be beneficial to our stockholders. In addition, these provisions could limit the price investors would be willing to pay in the future for shares of our common stock.

Our common stock is and will be subordinate to all of our existing and future indebtedness.

Shares of our common stock are common equity interests in us and, as such, will rank junior to all of our existing and future indebtedness and other liabilities. Additionally, our right to participate in a distribution of assets upon any of our subsidiaries’ liquidation or reorganization is subject to the prior claims of that subsidiary’s creditors.

The Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit your ability to buy and sell our common stock, which could depress the price of our shares.

FINRA has adopted rules that require broker-dealers to have reasonable grounds for believing that an investment is suitable for a customer before recommending that investment to the customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status and investment objectives, among other things. Under interpretations of these rules, FINRA believes that there is a high probability such speculative low-priced securities will not be suitable for at least some customers. Thus, FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our shares, have an adverse effect on the market for our shares, and thereby depress our share price.

RISKS RELATED TO AN EMERGING GROWTH COMPANY

We will face new challenges, increased costs and administrative responsibilities as a public company, particularly after we are no longer an “emerging growth company.”

As a publicly traded company with listed equity securities, we will need to comply with certain laws, regulations and requirements, including certain provisions of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, certain regulations of the Securities and Exchange Commission, or SEC, and certain of the OTCQB listing rules applicable to public companies. Complying with these statutes, regulations and requirements will occupy a significant amount of the time of our board of directors and management and will significantly increase our costs and expenses.

13

Table of Contents

We will need to:

institute a more comprehensive compliance framework;

update, evaluate and maintain a system of internal controls over financial reporting in compliance with the requirements of Section 404 of Sarbanes-Oxley and the related rules and regulations of the SEC;

prepare and distribute periodic public reports in compliance with our obligations under the federal securities laws;

revise our existing internal policies, such as those relating to disclosure controls and procedures and insider trading;

comply with SEC rules and guidelines including a requirement to provide our consolidated financial statements in interactive data format using eXtensible Business Reporting Language;

involve and retain to a greater degree outside counsel and accountants in the above activities; and

enhance our investor relations function.

However, for as long as we are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we are permitted to, and intend to, take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We will remain an emerging growth company for up to five years, although we would cease to be an emerging growth company as of December 31 of a particular year (i) if we had gross revenue of $1 billion or more in such year, (ii) if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 in such year, (iii) if at any point in such year, we would have issued more than $1 billion of non-convertible debt during the three-year period prior thereto or (iv) on the date on which we are deemed a “large accelerated issuer” as defined under the federal securities laws. For so long as we remain an emerging growth company, we will not be required to:

have an auditor report on our internal control over financial reporting pursuant to Section 404(b) of Sarbanes-Oxley;

comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis);

submit certain executive compensation matters to shareholder advisory votes pursuant to the “say on frequency” and “say on pay” provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the “say on golden parachute” provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; and

include detailed compensation discussion and analysis in our filings under the Securities Exchange Act of 1934, as amended, or Exchange Act, and instead may provide a reduced level of disclosure concerning executive compensation.

Although we intend to rely on the exemptions provided in the JOBS Act, the exact implications of the JOBS Act for us are still subject to interpretations and guidance by the SEC and other regulatory agencies. In addition, as our business grows, we may no longer satisfy the conditions of an emerging growth company. We are currently evaluating and monitoring developments with respect to these new rules, and we cannot assure you that we will be able to take advantage of all of the benefits from the JOBS Act. In addition, we also expect that being a public company subject to these rules and regulations will make it more expensive for us to maintain adequate director and officer liability insurance. These factors could also make it more difficult for us to attract and retain qualified executive officers and members of our board of directors, particularly to serve on our audit committee.

14

Table of Contents

Failure to establish and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and share price.

As a publicly traded company, we will be required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of Sarbanes-Oxley, which will require, beginning with the filing of our second annual report with the SEC, annual management assessments of the effectiveness of our internal control over financial reporting. However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. During the course of our testing, we may identify material weaknesses that we may not be able to remediate in time to meet our deadline for compliance with Section 404.

Testing and maintaining internal control can divert our management’s attention from other matters that are important to the operation of our business. We also expect the regulations to increase our legal and financial compliance costs, make it more difficult to attract and retain qualified executive officers and members of our board of directors, particularly to serve on our audit committee, and make some activities more difficult, time-consuming and costly. We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 and, when applicable to us, our independent registered public accounting firm may not be able or willing to issue an unqualified report on the effectiveness of our internal control over financial reporting. If we conclude that our internal control over financial reporting is not effective, it could have a material adverse effect on our financial condition, results of operations and market for our common stock, and could subject us to regulatory scrutiny.

RISKS RELATED TO OUR ENTERING INTO THE FIELD OF DEVELOPING ULTRASOUND DIAGNOSTICS TOOLS

We have no experience as a company conducting clinical trials.

We have no experience as a company conducting clinical trials and we cannot be certain that any clinical trials we may conduct will be completed on time or at all. Clinical trials require significant financial and management resources, and reliance on third-party clinical investigators, contract research organizations, or CROs, or consultants. Relying on third-party clinical investigators or CROs may force us to encounter delays that are outside of our control.

Clinical trials are expensive, time-consuming and difficult to design and implement.

Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidate is based on new technology, we expect that it will require extensive research and development and have substantial related costs. At this time we anticipate that the cost of required research will be at least $840,000, and the actual costs may be significantly higher. In order to conduct such research and development, we will need to raise additional capital through issuances of equity or debt which we may be unsuccessful in doing or on terms favorable to the Company.

15

Table of Contents

Our product candidate may not achieve commercialization and our commercial opportunity may be limited.

Development and obtaining regulatory approval for and commercializing our product candidate will require substantial additional funding and are prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance our product candidate through the development process.

Even if we receive FDA approval to market our product candidate for the diagnosis of malignancy in a tumor, we cannot assure you that our product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize our product candidate, our commercial opportunity will be limited.

If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidate.

We expect to spend substantial amounts to on the required research and clinical development of our product candidate. If approved, we will require significant additional amounts in order to launch and commercialize our product candidate. At this time we anticipate that the cost of required research will be at least $840,000, and the actual costs may be significantly higher.

We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidate.

Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidate.

We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidate, or grant licenses on terms unfavorable to us.

The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidate.

The regulatory approval pathway for our product candidate may be uncertain, complex, expensive and lengthy, and approval may not be obtained.

16

Table of Contents

We may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:

· the availability of financial resources to commence and complete the planned trial;

· reaching agreement on acceptable terms with prospective third parties to assist in the research, the terms of which can be subject to extensive negotiation and may vary significantly;

· obtaining approval at each clinical trial site by an independent institutional review board;

· recruiting suitable patients to participate in a trial;

· having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;

· clinical trial sites deviating from trial protocol or dropping out of a trial; or

· adding new clinical trial sites.

A clinical trial may be suspended or terminated by us, the institutional review board for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidate, the commercial prospects for our product candidate will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.

Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.

The patent we purchased was issued in August 2000 and expires in August 2020

The patent we purchased (Patent Number: 6,112,108) was issued in August 2000 and the patent protection under the patent expires in August 2020, leaving us a short period of time for protection under the patent.

Item 1B. Unresolved Staff Comments.

Not applicable to smaller reporting companies.

17

Table of Contents

Item 2. Description of Property

Item 3. Legal Proceedings

None.

Item 4. Mine Safety Disclosures

Not applicable.

18

Table of Contents

PART II

Item 5. Market for Common Equity and Related Stockholder Matters

Market Information

There is currently a very limited public market for our common shares. Our common shares are listed on the OTC Pink Sheets at this time, but there have been no trades. Trading in stocks quoted on the OTC Pink Sheets is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s operations or business prospects.

OTC Pink Sheet securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC Pink Sheet securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTC Pink Sheet issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

Number of Holders

As of June12, 2017, the 3,697,000 issued and outstanding shares of common stock were held by a total of 34 shareholders of record.

Dividends

No cash dividends were paid on our shares of common stock during the fiscal year ended December 31, 2016. We have not paid any cash dividends since September 18, 2015 (inception) and do not foresee declaring any cash dividends on our common stock in the foreseeable future.

Recent Sales of Unregistered Securities

The Company has 500,000,000, $0.001 par value shares of common stock authorized.

On September 19, 2015 we entered into a Share Exchange Agreement with the three (3) owners of Smile Central Dental Group, whereby we agreed to issue 3 million shares of common stock in exchange for all of the issued and outstanding shares of capital stock of Smile Central Dental Group. The three (3) owners of Smile Central Dental Group as a result became the executive officers and directors of Medico International.

19

Table of Contents

Medico International issued the securities to three (3) non-U.S. persons (as that term is defined in Regulation S of the Securities Act of 1933, as amended) in an offshore transaction in which we relied on the registration exemption provided for in Regulation S and/or Section 4(2) of the Securities Act of 1933, as amended (the “Act”), as the conditions of Regulation S were met, including but not limited to the following conditions:

·

Each of the parties receiving shares are residents and citizens of Singapore and were in Singapore at the time of the sale of the shares;

·

Each of the parties receiving shares agree to resell the shares only in accordance with Regulation S, pursuant to a registration under the Act, or pursuant to an available exemption from registration; and

·

The certificate representing the shares sold contain a legend that transfer of the shares is prohibited except in accordance with the provisions of Regulation S, pursuant to a registration under the Act, or pursuant to an available exemption from registration and the hold may engage in hedging transactions with regards to Medico’s common stock unless in compliance with the Act.

As of June 12, 2017, the 3,697,000 issued and outstanding shares of common stock were held by a total of 34 shareholders of record.

Item 6. Selected Financial Data

Not applicable to smaller reporting companies.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

Statements made in this Form 10-K that are not historical or current facts are "forward-looking statements". These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

OVERVIEW

We are a newly formed Nevada corporation organized for the purposes of acting as the holding company for Smile More Holdings Pte. Ltd., which is a Singapore corporation that owns and operates dental clinics in Singapore under the Smile Central name (referred to herein as “Smile Central”). Smile Central is a dental company employing the latest techniques in oral care and oral surgery in Singapore. Smile Central operates out of 5 locations in population-dense high foot traffic residential centers all over Singapore.

20

Table of Contents

Smile Central’s business model focuses on recruiting qualified and experienced dentists, supported by well-trained clinic support staff. Our dentists have post-graduate training in the fields of endodontics, orthodontics, periodontics, prosthodontics, paedodontics, oral surgery and implant dentistry. Hence, we are able to carry out procedures ranging from the routine cleaning and filling to the most complex ones involving aesthetics and surgery.

Years ended December 31, 2016 and December 31, 2015

For the year ended December 31, 2016 we earned Dental Service Revenue of $6,543,428 compared to Dental Service Revenue of $4,905,241 for the year ended December 31, 2015. Cost of Services for the year ended December 31, 2016 were $5,673,813 resulting in a Gross Profit of $869,615, compared to Cost of Services for year ended December 31, 2015 of $3,781,246 resulting in a gross profit of $1,123,995. Dental service revenue for the year ended December 31, 2016 increased by $1,638,187 over the year ended December 31, 2015 due to additional clinics, increased activity, patient treatments and patients.

Operating expenses were $1,884,053 for the year ended December 31, 2016, compared to $1,356,764 for the year ended December 31, 2015, due to additional clinics, increased operations, patient treatments, professional fees and resulting overhead. Operating expenses for the year ended December 31, 2016 were comprised of $845,684 for rental, $384,287 for general and administrative expenses, $299,956 for professional fees, $236,711 for depreciation, and $117,415 for staff costs, compared to $561,167 for rental, $158,781 for general and administrative expenses, $408,413 for professional fees, $139,930 for depreciation, and $88,473 for staff costs for the year ended December 31, 2015.

For the year ended December 31, 2016, we had other income of $102,832 and interest expense of $8,404, compared to $149,894 in other income and $5,833 in interest expense during the year ended December 31, 2015. The decrease in other income was attributed to a gain on forgiveness of debt for the year ending December 31, 2015, that did not re-occur in the year ended December 31, 2016.

LIQUIDITY AND CAPITAL RESOURCES

Years ended December 31, 2016 and December 31, 2015

Cash Flows

Our primary liquidity and capital requirements are for cost of services and administrative expenses. We fund our operations with cash generated from dental service revenue, capital contributions, and issuances of common stock.

Operating Activities

For the year ended December 31, 2016, net cash used in operating activities was $228,287. This negative cash flow related to our net loss of $920,010, adjusted for depreciation of $575,689, an increase in loss on disposal of equipment of $18,967, an increase in accounts receivable of $152,841, a decrease in other receivables of $69,000, an increase in prepaid expenses and deposits of $28,361, an increase in inventory of $29,062, an increase in accounts payable of $163,174, an increase in accrued and other payables of $72,703, and an increase in deferred revenue of $2,454.

This compared to net cash provided by operating activities during the year ended December 31, 2015 in the amount of $272,313.

21

Table of Contents

The Company’s consolidated financial statements accompanying this report have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of December 31, 2016, the Company has accumulated deficit of $1,161,700 since inception and has a working capital deficiency of $1,120,357.

Management's plans include raising capital through the equity markets to fund operations and eventually, generating profit through its business; however, there can be no assurance that the Company will be successful in such activities. The consolidated financial statements accompanying this report do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Investing Activities

For the year ended December 31, 2016, net cash used in investing activities was $438,226, compared to net cash of $361,286 used during the year ended December 31, 2015. The cash used for both periods was primarily driven by the cost of building and opening a total of four (4) dental clinics in Singapore during those periods, which resulted in an increase in the purchase of property, plant, and equipment for the year ended December 31, 2016.

Financing Activities

Net cash provided by financing activities was $620,243 for the year ended December 31, 2016. This was the result of issuance of shares for a total of $697,000, loans from related parties in the amount of $147,020, partially offset by the repayment of capital lease obligations in the amount of $223,777, loans from related parties in the amount of $581,503 and the repayment of capital lease obligations in the amount of $294,502, during the year ended December 31, 2015.

PLAN OF OPERATION

For the period from inception (January 20, 2014) through December 31, 2014, we incurred a net loss of $152,982 and total comprehensive loss of $146,584. However, during the year ended December 31, 2015, we incurred a net loss of $88,708 and total comprehensive loss of $81,732.

Subsequent to December 31, 2015, the Company raised $697,000 from its public offering of stock. The Company will use such funds for the building of additional clinics.

Recent Developments

Due to the continued consolidated losses experienced by the Company as the result of the losses of the Company’s wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), which included $232,769 for the fiscal year ended December 31, 2015, $801,760 for the fiscal year ended December 31, 2106, the Board of Directors of the Company believed it was in the best interests of the Company and its shareholders to dispose of Smile Central. In addition, the Company had provided Smile Central with over $600,000 in intra-company loans (the “Intra-Company Loan”).

22

Table of Contents

In addition, under the Share Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG.

Recent Developments

On March 7, 2017, the Company filed a Schedule 14C Information statement with the Securities and Exchange Commission in connection with the following action taken pursuant to the written consent of the shareholders holding a majority of the voting power of the Company’s issued and outstanding capital stock, dated as of February 28, 2017 (the “Written Consent”) authorizing the following:

Entry into a Stock Purchase Agreement dated February 28, 2017 (“Stock Purchase Agreement”), with Dr. Daniel Liew, the Company’s Chief Executive Office and a member of the Company’s Board of Directors, for the sale of all of the issued and outstanding ordinary shares of the Company’s 100% wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (the “Stock Purchase”).

The effect of the transactions set forth in the Stock Purchase Agreement is that the Company will no longer own and operate dental clinics in Singapore and will focus its efforts in the area of cancer diagnostics tools. The Company has purchased an ultrasound patent from Ramot University for Applied Research & Industrial Development Ltd. in Israel and is planning to develop the technology to diagnose malignancies in pelvic tumors. The company has also engaged Dr. Ron Tepper (phd), one of the investors of this patent, to help the company develop and bring the ultrasound diagnostics tools to market.

OFF-BALANCE SHEET ARRANGEMENTS

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules of the Securities Exchange Commission.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

The Company does not hold any assets or liabilities requiring disclosure under this item.

23

Table of Contents

Item 8. Financial Statements and Supplementary Data

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Medico International Inc.

We have audited the accompanying consolidated balance sheets of Medico International Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for the years then ended. Medico International Inc.’s management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Medico International Inc. as of December 31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company has incurred net losses and negative working capital since inception. These factors, and the need for additional financing in order for the Company to meet its business plans, raise substantial doubt about the Company’s ability to continue as a going concern.

/s/ Accell Audit & Compliance, P.A.

Tampa, Florida

June 16, 2017

4806 West Gandy Boulevard · Tampa, Florida 33611 · 813.440.6380

24

Table of Contents

Medico International Inc.

Consolidated Financial Statements

As of and For the Years Ended December 31, 2016 and 2015

MEDICO INTERNATIONAL INC.

CONSOLIDATED BALANCE SHEETS

December 31,
2016

December 31,
2015

ASSETS

Current Assets

Cash and cash equivalents

$ 287,754

$ 316,603

Accounts receivable

416,658

263,817

Other receivables

-

69,000

Prepaid expenses and deposits

222,084

193,723

Inventory

113,229

84,167

Total Current Assets

1,039,725

927,310

Property and equipment, net

1,037,656

993,968

TOTAL ASSETS

$ 2,077,381

$ 1,921,278

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities

Accounts payable

$ 633,247

$ 470,073

Accrued and other payables

186,894

114,191

Due to related parties

1,150,316

1,003,296

Deferred revenue

2,454

-

Capital lease obligations - current

187,171

212,570

Total Current Liabilities

2,160,082

1,800,130

Capital lease obligations

177,083

175,343

TOTAL LIABILITIES

2,337,165

1,975,473

COMMITMENTS AND CONTINGENCIES (NOTE 9)

STOCKHOLDERS’ DEFICIT

Common stock, $0.001 par value; 500,000,000 shares authorized, 3,697,000 and 3,000,000 shares issued and outstanding, respectively

3,697

3,000

Additional paid-in capital

867,424

171,121

Accumulated deficit

(1,161,700 )

(241,690 )

Accumulated other comprehensive gain

30,795

13,374

TOTAL STOCKHOLDERS' DEFICIT

(259,784 )

(54,195 )

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$ 2,077,381

$ 1,921,278

See the notes to the consolidated financial statements

25

Table of Contents

MEDICO INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Year Ended

Year Ended

December 31,

December 31,

2016

2015

DENTAL SERVICE REVENUE, NET

$ 6,543,428

$ 4,905,241

COST OF SERVICES

5,673,813

3,781,246

GROSS PROFIT

869,615

1,123,995

OPERATING EXPENSES

Rental

845,684

561,167

General and administrative

384,287

158,781

Professional fees

299,956

408,413

Depreciation

236,711

139,930

Staff costs

117,415

88,473

Total Operating Expenses

1,884,053

1,356,764

LOSS FROM OPERATIONS

(1,014,438 )

(232,769 )

OTHER INCOME/(EXPENSE)

Other income

102,832

149,894

Interest expense

(8,404 )

(5,833 )

94,428

144,061

LOSS BEFORE INCOME TAXES

(920,010 )

(88,708 )

Provision for income taxes

-

-

NET LOSS

$ (920,010 )

$ (88,708 )

OTHER COMPREHENSIVE LOSS

Foreign currency translation adjustments

17,421

6,976

TOTAL COMPREHENSIVE LOSS

$ (902,589 )

$ (81,732 )

Basic and Diluted Loss per Common Share

$ 0.25

$ (0.06 )

Basic and Diluted Weighted Average Common Shares Outstanding

3,647,486

1,495,371

See the notes to the consolidated financial statements

26

Table of Contents

MEDICO INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

Accumulated

Common Stock

Additional

Other

Total

Number
of Shares

Amount

Paid-in
Capital

Accumulated

Deficit

Comprehensive

Loss

Stockholders'

Deficit

Balance - December 31, 2014

907,320

$ 907

$ -

$ (152,982 )

$ 6,398

$ (145,677 )

Adjustment on shares exchange

2,092,680

2,093

69,257

-

-

71,350

Loans forgiven by shareholder

-

-

101,864

-

-

101,864

Net loss

-

-

-

(88,708 )

-

(88,708 )

Foreign currency translation adjustments

-

-

-

-

6,976

6,976

Balance - December 31, 2015

3,000,000

3,000

171,121

(241,690 )

13,374

(54,195 )

Adjustment on shares exchange

-

Issuance of shares

697,000

697

696,303

-

-

697,000

Net loss

-

-

-

(920,010 )

-

(920,010 )

Foreign currency translation adjustments

-

-

-

-

17,421

17,421

Balance - December 31, 2016

3,697,000

$ 3,697

$ 867,424

$ (1,161,700 )

$ 30,795

$ (259,784 )

See the notes to the consolidated financial statements

27

Table of Contents

MEDICO INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended

Year Ended

December 31,

December 31,

2016

2015

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

$ (920,010 )

$ (88,708 )

Adjustments to reconcile net loss to net cash from operating activities:

Bad debt

-

7,057

Depreciation

575,689

374,037

Loss on disposal of equipment

18,967

-

Changes in operating assets and liabilities:

Accounts receivable

(152,841 )

(18,769 )

Other receivables

69,000

(69,000 )

Prepaid expenses and deposits

(28,361 )

(91,405 )

Inventory

(29,062 )

(70,557 )

Accounts payable

163,174

362,877

Accrued and other payables

72,703

(133,219 )

Deferred revenue

2,454

-

Net cash (used in) provided by operating activities

(228,287 )

272,313

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property and equipment

(438,226 )

(361,286 )

Net cash used in investing activities

(438,226 )

(361,286 )

CASH FLOWS FROM FINANCING ACTIVITIES

Issuance of shares

697,000

-

Loans from related parties

147,020

581,503

Repayment of capital lease obligations

(223,777 )

(294,502 )

Net cash provided by financing activities

620,243

287,001

Effects on changes in foreign exchange rate

17,421

6,976

Net increase in cash and cash equivalents

(28,849 )

205,004

Cash and cash equivalents - beginning of period

316,603

111,599

Cash and cash equivalents - end of period

$ 287,754

$ 316,603

Supplemental Cash Flow Disclosures

Cash paid for interest

$ 8,404

$ 5,833

Cash paid for income taxes

$ -

$ -

Non-Cash Investing and Financing Activity:

Equipment acquired under capital lease obligations

$ 198,264

$ 467,404

Loans forgiven by shareholder

$ -

$ 101,864

Share exchange

$ -

$ 71,350

See the notes to the consolidated financial statements

28

Table of Contents

MEDICO INTERNATIONAL INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Nature of Operations

Medico International Inc. (the “Company” or “Medico”), a Nevada corporation, was formed by the owners and principals of Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), for the purpose of acting as the holding company for Smile Central and penetrating the U.S. financial markets. Smile Central owns six (6) dental clinics operating in Singapore. Smile Central’s operations were launched in January 2014 with three (3) clinics and in 2015, an additional two (2) clinics were opened. In 2016, one (1) additional dental clinic was opened. Smile Central plans to continue to expand its operations and create additional clinics in Singapore.

On September 19, 2015, the Company issued a total of 3,000,000 shares of common stock pursuant to the Share Exchange Agreement entered into among Medico, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. Pursuant to the Share Exchange Agreement, the Company agreed to issue 3,000,000 shares of its common stock in exchange for all of the issued and outstanding shares of capital stock of Smile Central, 30% of which was owned by Eminent Healthcare Pte. Ltd. and 70% of which was owned by Multi Care Pte. Ltd. The Company’s CFO, Liew Min Hin, owns 100% of Eminent Healthcare Pte. Ltd. The shares were issued pursuant to Section 4(2) of the Securities Act of 1993 (“Securities Act”) and are restricted shares as defined in the Securities Act.

Note 2: Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") on the accrual basis of accounting.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. We currently have no investments accounted for using the equity or cost methods of accounting.

Functional Currency

The Company's functional currency is the Singapore Dollar and reporting currency is the U.S. dollar. All transactions initiated in Singapore Dollar are translated into U.S. dollars in accordance with Accounting Standards Codification (“ASC”) 830-30, "Translation of Financial Statements," as follows:

i) Assets and liabilities at the rate of exchange in effect at the balance sheet date.

ii) Equity at historical rates.

iii) Revenue and expense items at the average rate of exchange prevailing during the period.

Adjustments arising from such translations are included in accumulated other comprehensive gain in stockholders’ deficit.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

29

Table of Contents

Cash and Cash Equivalents

Cash and cash equivalents consists of cash and all highly liquid investments with a maturity of three months or less.

The Company maintains its cash accounts primarily with banks located in Singapore and they are all denominated in Singapore dollar.

Accounts Receivables

Accounts receivable consist primarily of receivables from provided services. Management determines the allowance for doubtful accounts based on customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. On a continuing basis, management analyzes delinquent receivables, and once these receivables are determined to be uncollectible, they are written off against an existing allowance account. As of December 31, 2016 and 2015, the Company has determined that an allowance for doubtful accounts is not necessary as all accounts are considered fully collectible.

Inventory

Inventory is stated at the lower of cost or market. Cost is computed using weighted average cost, which approximates actual cost, on a first-in, first-out basis. Inventory on hand is evaluated on an on-going basis to determine if any items are obsolete or in excess of future needs. Items determined to be obsolete are reserved for. The Company provides for the possible inability to sell its inventory by providing an excess inventory reserve. As of December 31, 2016 and 2015 the Company determined that no reserve was required.

Property and Equipment

Property and equipment are stated at cost and are depreciated over their estimated useful lives using the straight-line method. Expenditures for ordinary maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and accumulated depreciation are eliminated from the account and any gain or loss is reflected on the consolidated statements of operations.

Estimated useful lives for computers are 1 ~ 3 years and useful lives for dental equipment, furniture and fittings, office equipment and lab equipment are 3 ~ 5 years. Renovations are included at the lessor of useful life or the life of the lease.

Impairment or Disposal of Long-Lived Assets

The Company evaluates its long-lived assets whenever significant events or changes in circumstances occur that indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted future net cash flows from the operations to which the assets relate, based on management’s best estimates using appropriate assumptions and projections at the time, to the carrying amount of the assets. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss is recognized equal to the amount by which the carrying amount exceeds the estimated fair value of the asset. No such impairment was indicated at December 31, 2016 and 2015.

Fair Value of Financial Instruments Estimates

The Company’s financial instruments including accounts receivable, accounts payable, accrued and other payables and due to related parties are carried at cost, which approximates fair value due to the short-term maturity of these instruments. The recorded value of the Company’s long-term debt approximates its fair value as it bears interest at a floating rate.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk include cash. At times, the Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management monitors the credit rating and concentration of risk with these financial institutions on a continuing basis to mitigate risk.

30

Table of Contents

Taxes Collected and Remitted to Governmental Authorities

The Company reports taxes collected from customers, which are primarily goods and service tax, on a net basis.

Revenue Recognition

Revenues are recognized when services are rendered, amounts are reliably measurable, and collectability is assured. Revenue is presented, net of goods and services tax, rebates and discounts.

Advertising

Advertising costs are expensed as incurred. Advertising costs totaled $53,917 and $13,536 for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

Current income tax liabilities for current and prior years are recognized at the amounts expected to be paid to the tax authorities, using the tax rates (and tax laws) that have been enacted or substantially enacted by the balance sheet date.

Deferred income tax assets/liabilities are recognized for all deductible/taxable temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements except when the deferred income tax assets/liabilities arise from the initial recognition of an asset or liability in a transaction that is not a business combination and at the time of the transaction, affects neither accounting nor taxable profit or loss.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Deferred income tax assets and liabilities are measured at:

(i) the tax rates that are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled, based on tax rates (and tax laws) that have been enacted or substantially enacted by the balance sheet date; and

(ii) the tax consequence that would follow from the manner in which the Company expects, at the balance sheet date, to recover or settle the carrying amounts of its assets and liabilities.

Current and deferred income taxes are recognized as income or expenses in the consolidated statements of operations.

Recent Accounting Pronouncements

In December 2016, the Financial Accounting Standards Board (FASB) has issued ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.” The amendments affect narrow aspects of the guidance issued in ASU 2014-09 including Loan Guarantee Fees, Contract Costs, Provisions for Losses on Construction-Type and Production-Type Contracts, Disclosure of Remaining Performance Obligations, Disclosure of Prior Period Performance Obligations, Contract Modifications, Contract Asset vs. Receivable, Refund Liability, Advertising Costs, Fixed Odds Wagering Contracts in the Casino Industry, and Costs Capitalized for Advisors to Private Funds and Public Funds. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements for FASB ASC Topic 606. Public entities should apply Topic 606 (and related amendments) for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein. The Company is currently evaluating the potential impact that the adoption of this ASU may have on its consolidated financial statements.

Management has considered all recent accounting pronouncements issued. The Company's management believes that these other recent pronouncements will not have a material effect on the Company's consolidated financial statements.

31

Table of Contents

Note 3: Going Concern

These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of December 31, 2016, the Company has an accumulated deficit of $1,161,700 since inception and has a working capital deficiency of $1,120,357.

Management's plans include raising capital through the equity markets to fund operations and eventually, generating profit through its business; however, there can be no assurance that the Company will be successful in such activities. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4: Property and Equipment

December 31,
2016

December 31,
2015

Dental equipment

$ 1,057,544

$ 835,949

Renovation

755,217

525,341

Computer

68,003

60,190

Office equipment

19,258

20,539

Lab equipment

6,679

6,135

Furniture and fittings

3,218

530

1,909,919

1,448,684

Less accumulated depreciation

(872,263 )

(454,716 )

$ 1,037,656

$ 993,968

Depreciation expense of approximately $576,000 and $374,000 was recorded by the Company for the years ended December 31, 2016 and 2015, respectively. Approximately $339,000 and $234,000 is included in the cost of services and approximately $237,000 and $140,000 is included in operating expenses on the Company’s consolidated statements of operations for the years ended December 31, 2016 and 2015, respectively.

Note 5: Capital Leases

The Company leases dental equipment under non-cancellable capital lease arrangements. The terms of those capital leases vary from 3 to 5 years and annual interest rates vary from 3% to 7%.

As of December 31, 2016, the future minimum lease payments under finance leases are as follows:

2017

$ 196,782

2018

118,886

2019

69,589

Total

385,257

Amount representing interest payments

(21,003 )

Present value of future minimum payments

364,254

Capital lease obligation, current portion

187,171

Capital lease obligation, long-term portion

$ 177,083

32

Table of Contents

Note 6: Related Parties Transactions

In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances were considered temporary in nature and were not formalized by a promissory note.

During the years ended December 31, 2016 and 2015, the Company received net advances of $147,020 and $581,503 by the way of loans from various officers. As of December 31, 2016 and 2015, the Company was obligated to its officers for unsecured, non-interest bearing demand loans with balances totaling $1,150,316 and $1,003,296, respectively.

During the year ended December 31, 2015, one of the Company’s officers forgave $101,864 of expenses paid on behalf of the Company, which was recorded as additional paid in capital.

Note 7: Common Stock

During the year ended December 31, 2016, the Company issued 697,000 shares at $1.00 per share in connection with its registration statement resulting in proceeds of $697,000.

As of December 31, 2016 and 2015, 3,697,000 and 3,000,000 shares of common stock were issued and outstanding, respectively.

Note 8: Income Taxes

The Company accounts for income taxes in accordance with the provisions of FASB ASC 740, Accounting for Uncertainty in Income Taxes. The Company files income tax returns in Singapore and there are currently no federal income tax examinations underway. The Company’s tax year of 2014 and forward are subject to examination by federal taxing authorities for at least five years.

The Company accounts for income taxes using an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The provision for income taxes includes:

2016

2015

Taxes – current

$ -

$ -

Taxes – deferred

-

-

Income tax expenses

$ -

$ -

The Company is subject to taxation in the United States and Singapore.

The provision for income taxes differs from the amounts which would be provided by applying the statutory income tax rate of 17% in Singapore and 34% in the United States to the net income (loss) before provision for income taxes for the following reasons:

2016

2015

Computed at the statutory rate

$ 312,803

$ 30,161

Difference in rates in Singapore

(139,261 )

(5,879 )

Non-deductible expenses

-

-

Change in valuation allowance

(173,542 )

(24,282 )

Actual tax expense

$ -

$ -

33

Table of Contents

Following are the details of deferred tax assets and its valuation allowance:

December 31,
2016

December 31,
2015

Deferred tax assets

Net operating loss carry forwards

$ 1,161,700

$ 241,690

Deferred tax asset before valuation allowance

223,831

50,289

Valuation allowance

Beginning balance

(50,289 )

(26,007 )

Changes during the period

(173,542 )

(24,282 )

Ending balance

(223,831 )

(50,289 )

$ -

$ -

The related deferred tax benefit on the above unutilized tax losses has a full valuation allowance not recognized against it as there is no certainty of its realization. Management has evaluated tax positions in accordance with ASC 740 and has not identified any significant tax positions, other than those disclosed.

The Company has yet to file its tax return with the Inland Revenue Authority of Singapore for the year of assessment of 2016.

Due to the change in ownership provisions of the income tax laws of United States of America, net operating loss carry forwards of approximately $1,161,700, which expire commencing in fiscal 2035, for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.

Note 9: Commitments and Contingencies

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB 450-20-50, Contingencies. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals. As of December 31, 2016, the Company is not aware of any contingent liabilities that should be reflected in the consolidated financial statements.

The Company leases space for its dental clinics under non-cancelable operating leases. During the years ended December 31, 2016 and 2015, the Company paid rent expenses of $845,684 and $561,167, respectively.

As of December 31, 2016, the approximate future aggregate minimum lease payments under the non-cancellable operating leases were as follows:

2017

$ 790,578

2018

457,567

2019

110,592

$ 1,358,737

Note 10: Subsequent Events

On February 14, 2017, the Company entered into four lease agreements for property, plant, and equipment, which totaled $948,616 Singapore dollars ($655,494 USD). he Company agreed to make monthly payments in regards to these agreements, which end in January 2020.

Due to the continued consolidated losses experience by the Company as the result of the losses of the Company’s wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), the Board of Directors of the Company believed it was in the best interests of the Company and its shareholders to dispose of Smile Central. In addition, the Company had provided Smile Central with over $600,000 in intra-company loans (the “Intra-Company Loan”).

In addition, under the Share Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG.

34

Table of Contents

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Management’s Report on Internal Controls over Financial Disclosure Controls and Procedures

Disclosure Controls and Procedures. Our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), in connection with the preparation of this Annual Report on Form 10-K, as of December 31, 2016.

Based on the review described above, our Chief Executive Officer and Chief Financial Officer determined that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Internal Control Over Financial Reporting. Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. In addition, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Our management assessed our internal control over financial reporting as of December 31, 2016 based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on such assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2016 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

35

Table of Contents

This annual report on Form 10-K does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this annual report on Form 10-K.

Changes in Internal Controls

There were no changes in our internal control over financial reporting that occurred during the fourth quarter ended December 31, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

In addition, under the Share Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG.

36

Table of Contents

PART III

Item 10. Directors, Executive Officers, Promoters and Control Persons of the Company

(a) – (b) Identification of Directors and Executive Officers.

The Company: The following table identifies all of the members of the Company’s Board of Directors and its Executive Officers. The members of the Board serve until the next annual meeting and a successor is appointed and qualified, or until resignation or removal.

Name

Age

Positions Held

Date of Appointment

Jiang Chun Yan

34

Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Member of the Board of Directors

June 5, 2017

The Company currently does not have any employees.

(d) Family relationships. None.

(e) Business experience

Jiang Chun Yan - Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Member of the Board of Directors

Jiang Chun Yan holds an MBA. He completed his studies at the University of Shanghai in 2010. He worked as a manager at Shindo Industries in South Korea from 2011 until 2016. He spent 2016 and 2017 looking for new opportunities prior to becoming an officer and director of the Company.

(f) Involvement in certain legal proceedings.

None of the Company’s executive officers or directors have been involved in any legal proceedings during the past five (5) years.

37

Table of Contents

(g) Promoters and control persons.

As a result of the Stock Purchase Agreement, Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”), owns 3,000,000 shares of the Company’s common stock, which represents 81.14% of the total shares issued and outstanding. Therefore, TSG is a controlling shareholder of the Company. TSG has not been a party to any legal proceedings at any time during the past five (5) years.

Section 16(a) Beneficial Ownership Reporting Compliance

Not applicable.

Code of Ethics

We do not currently have a Code of Ethics in place for the Company. Our business operations are not complex and are very limited. The Company seeks advice and counsel from outside experts such as our lawyers and accountants on matters relating to corporate governance and financial reporting.

Audit Committee

We do not have an Audit Committee. The Company's board of directors perform some of the same functions of an Audit Committee, such as: recommending a firm of independent certified public accountants to audit the financial statements; reviewing the auditors' independence, the financial statements and their audit report; and reviewing management's administration of the system of internal accounting controls. The Company does not currently have a written audit committee charter or similar document.

Item 11. Executive Compensation

The Company was incorporated in September 2015 and therefore has not paid any salaries to its executive officers. Currently, the Company’s executive officers are compensated only for the services that they provide to Smile Central and the various clinics as detailed below. The Company does not have any plans to the executive officers salaries.

38

Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth certain information concerning the number of shares of our common stock owned beneficially as of June 5, 2017 (after giving effect to the transactions under the Stock Purchase Agreement) by: (i) each person (including any group) known to us to own more than five percent (5%) of any class of our voting securities, (ii) members of our Board of Directors, and or (iii) our executive officers. Unless otherwise indicated, the stockholder listed possesses sole voting and investment power with respect to the shares shown.

Title of Class

Name and

Address of beneficial

owner

Amount and nature of beneficial ownership⁽¹⁾

Percent of class

Common Stock

Targeted Solutions Global Limited

The Bristol Office, 2^nd Fl., 5 High Street, Westbury on Trym

[Bristol, United Kingdom

3,000,000

81.14 %

Common Stock

Jiang Chun Yan ⁽²⁾

The Bristol Office, 2^nd Fl., 5 High Street, Westbury on Trym

Bristol, United Kingdom

-0-

0 %

(1) A beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person's actual ownership or voting power with respect to the number of shares of common stock actually outstanding on April 1, 2016.

As of June 12, 2017, there were 3,697,000 shares of our common stock issued and outstanding.

(2) Jiang Chun Yan was appointed an officer and director of the Company effective June 5, 2017.

39

Table of Contents

The Company has not adopted any equity compensation plans and does not anticipate adopting any equity compensation plans in the near future. Notwithstanding the foregoing, because the Company has limited cash resources at this time, it may issue shares or options to or enter into obligations that are convertible into shares of common stock with its employees and consultants as payment for services or as discretionary bonuses. The Company does not have any arrangements for such issuances or arrangements at this time.

Item 13. Certain Relationships and Related Transactions, and Director Independence

On September 19, 2015, we issued a total of 3,000,000 shares of common stock pursuant to the Share Exchange Agreement entered into among us, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd., which were the owners of Smile More Holdings Pte. Ltd. Pursuant to the Share Exchange Agreement, we agreed to issue 3,000,000 shares of our common stock in exchange for all of the issued and outstanding shares of capital stock of Smile More Holdings Pte. Ltd. (“Smile Shares”), 30% of which was owned by Eminent Healthcare Pte. Ltd. and 70% of which was owned by Multi Care Pte. Ltd. Our former CFO, Liew Min Hin, owns 100% of Eminent Healthcare Pte. Ltd. The shares were issued pursuant to Section 4(2) of the Securities Act and are restricted shares as defined in the Securities Act. As part of the Stock Purchase Agreement, the Company transferred the Smile Shares to Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd.

During the year ended December 31, 2015, one of the Company’s officers forgave $101,864 of expenses paid on behalf of the Company, which was recorded as additional paid in capital.

Item 14. Principal Accounting Fees and Services

The aggregate fees billed by our independent auditors, Accell Audit & Compliance, P.A., for professional services rendered for the audit of our annual financial statements for the years ended December 31, 2016 and 2015 are provided below.

Fee Category

Year Ended December 31,
2016

Year Ended December 31,
2015

Audit Fees

$
34,500

$ 21,500

Audit-Related Fees

-

-

Tax Fees

-

-

All Other Fees

-

-

Total Fees

$
34,500

$ 21,500

Audit committee policies & procedures

The company does not currently have a standing audit committee. The above services were approved by the company’s Board of Directors.

40

Table of Contents

PART IV

Item 15. Exhibits

The following exhibits are included as part of this report by reference:

10.1

Share Exchange Agreement, dated May 29, 2017, by and between the Medico International Inc., Eminent Healthcare Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company.

31.1

Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

32.1

Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

41

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDICO INTERNATIONAL INC.

Dated June 19, 2017

By:

/s/ Jiang Chun Yan

Name:

Jiang Chun Yan

Title:

Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Financial and Accounting Officer), and Director

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures

Title

Date

/s/ Jiang Chun Yan

Chief Executive Officer, Chief Financial Officer, and Director

June 19, 2017

Jiang Chun Yan

EX-10.1 2 mddt_ex101.htm SHARE EXCHANGE AGREEMENT mddt_ex101.htm

EXHIBIT 10.1

SHARE EXCHANGE AGREEMENT

THIS SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of the _____ day of May, 2017 (this “Agreement”) is entered into by and among, Medico International Inc., a Nevada corporation (“Medico”); Eminent Healthcare Pte. Ltd., a Singaporean corporation (“EH”); Multi Care Pte. LTD., a Singaporean corporation (“MC”) and Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”) (each of EH and MC are referred to herein as a “Purchaser” and collectively, the “Purchasers”). Medico, Purchasers and TSG are referred to singularly as a “Party” and collectively as the “Parties.”

WITNESSETH:

WHEREAS, Purchasers own 3,000,000 collectively of the issued and outstanding shares of Medico (EH owns 900,000 shares and MC owns 2,100,000 shares), out of a total of 3,697,000 shares issued and outstanding;

WHEREAS, the owner of EH is an executive officer and director of Medico;

WHEREAS, Medico owns 100% of the issued and outstanding shares of Smile More Holdings PTE. LTD., a Singaporean corporation, its wholly-owned subsidiary (the “Subsidiary”) and has provided the Subsidiary with certain loans and advances (the “Intra- Company Loans”);

WHEREAS, TSG has the right and ability to deliver and cause the assignment of US Patent No. 6,112,108 “Method for diagnosing malignancy in pelvic tumors (the “Patent”) which consists of technology and know-how for the development of an ultrasound device for the diagnosis of pelvic tumors;

WHEREAS, Purchasers wish to acquire all of the issued and outstanding shares of capital stock of the Subsidiary (referred to hereinafter as the “Subsidiary Shares”), with the purpose of owning and operating the Subsidiary as the Subsidiary’s sole owners; and

WHEREAS, Medico, Purchasers and TSG propose to enter into this Agreement which provides, among other things, that:

(a) TSG will (i) assign and deliver the Patent to Medico and (ii) pay $200,000 to the Purchasers;

(b) Purchasers will deliver the aggregate total of 3,000,000 shares of Medico’s common stock to TSG;

(d) Medico shall release the Subsidiary from the Intra-Company Loan (the “Release”).

NOW, THEREFORE, in consideration, of the promises and of the mutual representations, warranties and agreements set forth herein, the Parties hereto agree as follows:

ARTICLE I

DEFINITIONS

Section 1.01. Definitions. The following terms shall have the following respective meanings:

“Business Day”

a day (other than a Saturday) on which banks in Nevada are open for business throughout their normal business hours;

“Closing”

the closing of the transactions contemplated by this Agreement;

“Completion”

completion of acquisition of the Subsidiary Shares by the Purchasers and the return of the Medico Shares to Medico (as such term is defined below) in accordance with the terms and conditions of this Agreement;

“Encumbrance”

any mortgage, charge, pledge, lien, (otherwise than arising by statute or operation of law), equities, hypothecation or other encumbrance, priority or security interest, preemptive right deferred purchase, title retention, leasing, sale-and-repurchase or sale-and-leaseback arrangement whatsoever over or in any property, assets or rights of whatsoever nature and includes any agreement for any of the same and reference to “Encumbrances” shall be construed accordingly;

“US”

United States of America;

“United States Dollars” or “US$”

United States dollars;

Section 1.02. Rules of Construction.

(a) Unless the context otherwise requires, as used in this Agreement: (i) “including” means “including, without limitation”; (ii) words in the singular include the plural; (iii) words in the plural include the singular; (iv) words applicable to one gender shall be construed to apply to each gender; (v) the terms “hereof,” “herein,” “hereby,” “hereto” and derivative or similar words refer to this entire Agreement,; (vi) the terms “Article” and “Section” shall refer to the specified Article or Section of or to this Agreement (vii) the term “day” shall refer to calendar days.

(b) Titles and headings to Articles and Sections are inserted for convenience of reference only, and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

ARTICLE II

THE TRANSFERS

Section 2.01 Transfers of Patent and Shares.

(a) Subject to and upon the terms and conditions of this Agreement, on the Closing Date (as defined hereafter), the following transfers shall take place, all simultaneous with each other and each transfer contingent upon all such transfers:

(i) TSG shall assign and deliver the Patent to Medico;

(ii) TSG shall pay Two Hundred Thousand US Dollars (USD $200,000) to the Purchasers;

(iii) Purchasers shall transfer and deliver to TSG all of the shares of common stock of Medico owned by the Purchasers, which amount of shares shall equal Three Million (3,000,000) shares (the “Medico Shares”);

(iv) Medico will transfer all of the Subsidiary Shares to the Purchasers and shall allocated thirty percent (30%) to EH and seventy percent (70%) to MC; and

(v) Medico shall provide the Subsidiary with a Waiver and Release to forgive the Intra-Company Loan.

(b) The transfers described above are referred to herein as a “Transfer” and collectively as the “Transfers”. All assets, shares and property that are part of the Transfers shall be acquired by the respective recipient free from all Encumbrances together with all rights now or hereafter attaching thereto and the Subsidiary shall continue to operate in its normal course of business.

(c) The Share Exchange shall take place upon the terms and conditions provided for in this Agreement and in accordance with applicable law. If the Closing does not occur as set forth in Section 2.02 of this Agreement due to one Party’s failure to perform, then either of the other Parties may terminate this Agreement.

Section 2.02. Closing Location. The Closing of the Share Exchange and the other transactions contemplated by this Agreement will occur as soon as possible (the “Closing Date.

Section 2.03. Purchasers’ Closing Documents. At the Closing, Purchasers shall tender the following:

(a) Original stock certificate(s) representing the Medico Shares, along with such stock powers, affidavit of cancellation or such other form or document required by Medico’s transfer agent for the transfer of the Medico Shares to TSG;

(b) Certified copies of resolutions of the Board of Directors (or similar governing body) of each Purchaser in a form satisfactory to the other Parties, acting reasonably, authorizing:

(i) the execution and delivery of this Agreement by each Purchaser; and

(ii) the sale and transfer of such respective Purchaser’s portion of the Medico Shares to TSG; and

Section 2.04. Medico’s Closing Documents. At the Closing, Medico will tender the following:

(a) A certified copy(ies) of resolutions of the Board of Directors of Medico in a form satisfactory to the other Parties, acting reasonably, authorizing:

(i) the execution and delivery of this Agreement by Medico; and

(ii) the sale and transfer of the Subsidiary Shares to Purchasers.

(b) New stock certificates issued by the Subsidiary in the name of the Purchasers representing the Subsidiary Shares;

(d) A certificate executed by a duly appointed officer of Medico certifying that the conditions in Section 10.01(b) have been satisfied.

Section 2.05. TSG’s Closing Documents. At the Closing, TSG will tender the following:

(a) A certified copy(ies) of resolutions of the Board of Directors of TSG in a form satisfactory to the other Parties, acting reasonably, authorizing:

(i) the execution and delivery of this Agreement by Medico;

(ii) the payment of Two Hundred Thousand US Dollars to the Purchasers; and

(iii) the sale and assignment of the Patent to Medico.

(b) A certificate executed by a duly appointed officer of TSG certifying that the conditions in Section 9.01(b) have been satisfied.

ARTICLE III

REPRESENTATIONS AND WARRANTIES

Section 3.01. Each Party represents and warrants to the other Party that each of the warranties it makes is accurate in all respects and not misleading as at the date of this Agreement.

Section 3.02. Each Party undertakes to disclose in writing to the other Party anything which is or may constitute a breach of or be inconsistent with any of the warranties immediately upon the same coming to its notice at the time of and after Completion.

Section 3.03. Each Party agrees that each of the warranties it makes shall be construed as a separate and independent warranty and (except where expressly provided to the contrary) shall not be limited or restricted by reference to or inference from the terms of any other warranty or any other term of this Agreement.

Section 3.04. Each Party acknowledges that the restrictions contained in Section 13.01 shall continue to apply after the Closing without limit in time.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF MEDICO

Medico represents and warrants to the other Parties as follows:

Section 4.01. Organization, Standing and Authority; Foreign Qualification. Medico is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada and has all requisite corporate power and authority to own, lease and operate its properties and to conduct its business as presently conducted and as proposed to be conducted and is duly qualified or licensed as a foreign corporation in good standing in each jurisdiction in which the character of its properties or the nature of its business activities require such qualification.

Section 4.02. Corporate Authorization. The execution, delivery and performance by Medico of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of Medico, and this Agreement constitutes a valid and binding agreement of Medico.

Section 4.03. Capitalization. All of the Subsidiary Shares are duly authorized, validly issued, fully paid and non-assessable. There are no outstanding options, warrants, agreements or rights to subscribe for or to purchase, or commitments to issue, shares of capital stock in the Subsidiary or any other security of the Subsidiary or any plan for any of the foregoing.

Section 4.04. Sale of Subsidiary Shares. Upon completion of the purchase and sale of the Subsidiary Shares, Purchasers shall be the beneficial and record holder of the Subsidiary Shares.

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS

The Purchasers represent and warrant to the other Parties as follows:

Section 5.01. Organization, Standing and Authority; Foreign Qualification.

The Purchasers are corporations duly organized, validly existing and in good standing under the laws of Singapore and have all requisite corporate power and authority to own, lease and operate their properties and to conduct their businesses as presently conducted and as proposed to be conducted and are duly qualified or licensed as foreign corporations in good standing in each jurisdiction in which the character of their properties or the nature of their business activities require such qualification.

Section 5.02. Authorization. The execution, delivery and performance by Purchasers of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary actions, as the case may be, on the part of Purchasers. Purchasers have duly executed and delivered this Agreement and this Agreement constitutes a valid and binding agreement of Purchasers.

Section 5.03. Cooperation. If required by applicable securities laws or order of a securities regulatory authority, stock exchange or other regulatory authority, Purchasers will execute, deliver, file and otherwise assist TSG or Medico in filing such reports, undertakings and other documents as may be required with respect to the transfer of the Medico Shares or the transfer of the Subsidiary Shares.

Section 5.04. Tax Advice. Purchasers are solely responsible for obtaining such legal, including tax, advice as any of them considers necessary or appropriate in connection with the execution, delivery and performance by Purchasers of this Agreement and the transactions contemplated herein.

Section 5.05. No Conflict.

The execution, delivery and performance of this Agreement and the completion of the transactions contemplated herein will not:

(a) violate any provision of the Articles of Incorporation, Bylaws or other charter or organizational document of Purchasers;

(b) violate, conflict with or result in the breach of any of the terms of, result in any modification of the effect of, otherwise give any other contracting party the right to terminate, or constitute (or with notice or lapse of time or both constitute) a default under, any contract to which Purchasers is a party or by or to which either of its assets or properties, may be bound or subject;

(c) violate any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding upon, or any agreement with, or condition imposed by, any governmental or regulatory body, foreign or domestic, binding upon Purchasers or upon the securities, assets or business of Purchasers;

(d) violate any statute, law or regulation of any jurisdiction as such statute, law or regulation relates to Purchasers or to the securities, properties or business of Purchasers; or

(e) result in the breach of any of the terms or conditions of, constitute a default under, or otherwise cause an impairment of, any permit or license held by Purchasers.

Section 5.06. Compliance with Laws. To the best of Purchasers’ knowledge, neither Purchaser is in violation of any applicable order, judgment, injunction, award or decree nor are they in violation of any federal, provincial, state, local, municipal or foreign law, ordinance or regulation or any other requirement of any governmental or regulatory body, court or arbitrator, other than those violations which, in the aggregate, would not have a material adverse effect on the Subsidiary or Purchasers and have not received written notice that any violation is being alleged.

Section 5.07. Material Information. This Agreement and all other information provided in writing by Purchasers or representatives thereof to Medico, taken as a whole, do not contain any untrue statement of a material fact or omit to state a material fact necessary to make any statement contained herein or therein not misleading. There are no facts or conditions, which have not been disclosed to Medico in writing which, individually or in the aggregate, could have a material adverse effect on Purchasers or a material adverse effect on the ability of Purchasers to perform any of their obligations pursuant to this Agreement.

ARTICLE VI

REPRESENTATIONS AND WARRANTIEES OF TSG

TSG represents and warrants to the other Parties as follows:

Section 6.01. Organization, Standing and Authority; Foreign Qualification.

TSG is a corporation duly organized, validly existing and in good standing under the laws of the United Kingdom and has all requisite corporate power and authority to own, lease and operate its property and to conduct its business as presently conducted and as proposed to be conducted and is duly qualified or licensed as a foreign corporation in good standing in each jurisdiction in which the character of its property or the nature of its business activities require such qualification.

Section 6.02. Authorization. The execution, delivery and performance by TSG this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary actions, as the case may be, on the part of TSG. TSG has duly executed and delivered this Agreement and this Agreement constitutes a valid and binding agreement of TSG.

Section 6.03. Cooperation. If required by applicable securities laws or order of a securities regulatory authority, stock exchange or other regulatory authority, Purchasers will execute, deliver, file and otherwise assist TSG or Medico in filing such reports, undertakings and other documents as may be required with respect to the transfer of the Medico Shares or the transfer of the Subsidiary Shares.

Section 6.04. Tax Advice. TSG is solely responsible for obtaining such legal, including tax, advice as it considers necessary or appropriate in connection with the execution, delivery and performance by TSG of this Agreement and the transactions contemplated herein.

Section 6.05. No Conflict.

The execution, delivery and performance of this Agreement and the completion of the transactions contemplated herein will not:

(a) violate any provision of the Articles of Incorporation, Bylaws or other charter or organizational document of TSG;

(c) violate any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding upon, or any agreement with, or condition imposed by, any governmental or regulatory body, foreign or domestic, binding upon TSG or upon the securities, assets or business of TSG;

(d) violate any statute, law or regulation of any jurisdiction as such statute, law or regulation relates to Purchasers or to the securities, properties or business of TSG; or

(e) result in the breach of any of the terms or conditions of, constitute a default under, or otherwise cause an impairment of, any permit or license held by TSG.

Section 6.06. Compliance with Laws. To the best of TSG’s knowledge, TSG is not in violation of any applicable order, judgment, injunction, award or decree nor is it in violation of any federal, provincial, state, local, municipal or foreign law, ordinance or regulation or any other requirement of any governmental or regulatory body, court or arbitrator, other than those violations which, in the aggregate, would not have a material adverse effect on the TSG or the Patent and has not received written notice that any violation is being alleged.

Section 6.07. Material Information. This Agreement and all other information provided in writing by TSG or representatives thereof to Medico or Purchasers, taken as a whole, do not contain any untrue statement of a material fact or omit to state a material fact necessary to make any statement contained herein or therein not misleading. There are no facts or conditions, which have not been disclosed to Medico or Purchaser in writing which, individually or in the aggregate, could have a material adverse effect on TSG or the Patent or a material adverse effect on the ability of TSG to perform any of its obligations pursuant to this Agreement.

ARTICLE VII

COVENANTS AND AGREEMENTS OF PURCHASERS

Section 7.01. Conduct of Businesses in the Ordinary Course. From the date of this Agreement to the Closing Date, Purchasers shall cause the Subsidiary to conduct its business substantially and the businesses of its subsidiaries in the manner in which it is currently conducted.

Section 7.02. Preservation of Permits and Services. From the date of this Agreement to the Closing Date, Purchasers shall cause the Subsidiary to use its best efforts to preserve any permits and licenses in full force and effect and to keep available the services, and preserve the goodwill, of its present managers, officers, employees, agents, and consultants.

Section 7.03. Conduct Pending the Closing Date. From the date of this Agreement to the Closing Date: (a) Purchasers shall cause the Subsidiary to use its best efforts to conduct its affairs in such a manner so that, except as otherwise contemplated or permitted by this Agreement, the representations and warranties contained in Article V shall continue to be true and correct on and as of the Closing Date as if made on and as of the Closing Date; and (b) Purchasers shall promptly notify Medico of any event, condition or circumstance that would constitute a violation or breach of this Agreement by Purchasers.

ARTICLE VIII

COVENANTS AND AGREEMENTS OF MEDICO

Section 8.01. Conduct of Businesses in the Ordinary Course. From the date of this Agreement to the Closing Date, Medico shall conduct its businesses substantially in the manner in which it is currently conducted.

Section 8.02. Conduct of Medico Pending the Closing. From the date hereof through the Closing Date:

(a) Medico shall use its best efforts to conduct its affairs in such a manner so that, except as otherwise contemplated or permitted by this Agreement, the representations and warranties contained in Article IV shall continue to be true and correct on and as of the Closing Date as if made on and as of the Closing Date; and

(b) Medico shall promptly notify Purchasers of any event, condition or circumstance occurring from the date hereof through the Closing Date that would constitute a violation or breach of this Agreement by Medico.

ARTICLE IX

CONDITIONS PRECEDENT TO THE OBLIGATION OF MEDICO TO CLOSE

The obligations of Medico to be performed by it at the Closing pursuant to this Agreement are subject to the fulfillment on or before the Closing Date, of each of the following conditions, any one or more of which may be waived by it, to the extent permitted by law:

Section 9.01. Representations and Covenants. (a) The representations and warranties of Purchasers contained in this Agreement shall be true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date, except that any of such representations and warranties that are given as of a particular date and relate solely to a particular date or period shall be true as of such date or period; and

(b) The Purchasers and TSG shall have performed and complied with all covenants and agreements required by this Agreement to be performed or complied with by each of them on or before the Closing Date. The Purchasers shall have delivered to Medico a certificate, dated the Closing Date, and signed by Purchasers to the foregoing effect.

Section 9.02. Governmental Permits and Approvals.

(a) All approvals, authorizations, consents, permits and licenses from governmental and regulatory bodies required for the transactions contemplated by this Agreement and to permit the business currently carried on by the Subsidiary to continue to be carried on substantially in the same manner immediately following the Closing Date shall have been obtained and shall be in full force and effect, and Medico shall have been furnished with appropriate evidence, reasonably satisfactory to them, of the granting of such approvals, authorizations, consents, permits and licenses; and

(b) There shall not have been any action taken by any court, governmental or regulatory body then prohibiting or making illegal on the Closing Date the transactions contemplated by this Agreement.

Section 9.03. Third Party Consents. All consents, permits and approvals from parties to contracts with the Subsidiary that may be required in connection with the performance by Purchasers hereunder or the continuance of such contracts in full force and effect after the Closing Date, shall have been obtained.

Section 9.04. Litigation. No action, suit or proceeding shall have been instituted and be continuing or be threatened by any person to restrain, modify or prevent the carrying out of the transactions contemplated hereby, or to seek damages in connection with such transactions, or that has or could have a material adverse effect on the Subsidiary, Purchasers, or on the Subsidiary Shares.

Section 9.05. Closing Documents. The Purchasers shall have executed and delivered the documents described in Section 2.03 above.

ARTICLE X

CONDITIONS PRECEDENT TO THE OBLIGATION OF THE PURCHASERS TO CLOSE

The obligations of Purchasers to be performed by them at the Closing pursuant to this Agreement are subject to the fulfillment, on or before the Closing Date, of each the following conditions, any one or more of which may be waived by them, to the extent permitted by law:

Section 10.01. Representations and Covenants. (a) The representations and warranties of Medico contained in this Agreement shall be true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date, except that any of such representations and warranties that are given as of a particular date and relate solely to a particular date or period shall be true as of such date or period; and

(b) Medico shall have performed and complied with all covenants and agreements required by this Agreement to be performed or complied with by it on or before the Closing Date. Medico shall have delivered to Purchasers a certificate dated the Closing Date, and signed by an authorized signatory of Medico to the foregoing effect.

Section 10.02. Closing Documents. Medico shall have executed and delivered the documents described in Section 2.04 above.

ARTICLE XI

CONDITIONS PRECEDENT TO THE OBLIGATION OF TSG TO CLOSE

The obligations of TSG to be performed by them at the Closing pursuant to this Agreement are subject to the fulfillment, on or before the Closing Date, of each the following conditions, any one or more of which may be waived by them, to the extent permitted by law:

Section 11.01. Representations and Covenants. (a) The representations and warranties of TSG contained in this Agreement shall be true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date, except that any of such representations and warranties that are given as of a particular date and relate solely to a particular date or period shall be true as of such date or period; and

(b) TSG shall have performed and complied with all covenants and agreements required by this Agreement to be performed or complied with by it on or before the Closing Date. TSG shall have delivered to Medico a certificate dated the Closing Date, and signed by an authorized signatory of Medico to the foregoing effect.

Section 11.02. Closing Documents. TSG shall have executed and delivered the documents described in Section 2.05 above.

ARTICLE XII

TERMINATION

Section 12.01. Termination.

(a) Notwithstanding anything to the contrary in this Agreement, this Agreement may be terminated and the Share Exchange and the other transactions contemplated by this Agreement shall be abandoned at any time prior to the Closing:

(i) by mutual written consent of Purchasers and Medico;

(ii) by either Purchasers or Medico in the event that a temporary restraining order, preliminary or permanent injunction or other judicial order preventing the consummation of the Share Exchange or any of the other transactions contemplated hereby shall have become final and non-appealable; provided, that, the party seeking to terminate this Agreement pursuant to this clause (ii) shall have used all commercially reasonable efforts to have such order, injunction or other order vacated;

(iii) by Medico (a) if Medico is not then in material breach of this Agreement and if there shall have been any breach by Purchasers (which has not been waived) of one or more of its representations or warranties, covenants or agreements set forth in this Agreement, which breach or breaches (A) would give rise to the failure of a condition set forth in Article VIII, and (B) shall not have been cured within thirty (30) days following receipt by Purchasers of written notice of such breach, or such longer period in the event that such breach cannot reasonably be expected to be cured within such 30‑day period and Purchasers is diligently pursuing such cure, or (b) if Medico has not received results satisfactory to it, in its sole discretion, from its due diligence review of the Subsidiary and its operations; or

(iv) by Purchasers if they are not then in material breach of this Agreement and if there shall have been any breach by Medico (which has not been waived) of one or more of its representations or warranties, covenants or agreements set forth in this Agreement, which breach or breaches (A) would give rise to the failure of a condition set forth in Article IX, and (B) shall not have been cured within thirty (30) days following receipt by Medico of written notice of such breach.

(b) In the event of termination by Purchasers or Medico pursuant to this Section 10.01, written notice thereof shall forthwith be given to the other Party and the transactions contemplated by this Agreement shall be terminated, without further action by any Party.

Section 12.02. Effect of Termination. If this Agreement is terminated and the transactions contemplated hereby are abandoned as described in Section 10.01, this Agreement shall become null and void and of no further force and effect, except for the provisions of (i) Section 10.01 and this Section 10.02; and (ii) Section 12.01 relating to publicity. Nothing in this Section 10.02 shall be deemed to release any Party from any liability for any breach by such Party of the terms, conditions, covenants and other provisions of this Agreement or to impair the right of any Party to compel specific performance by any other Party of its obligations under this Agreement.

ARTICLE XIII

POST-CLOSING COVENANTS

Section 13.01 Purchasers’ Covenants. The Purchasers hereby covenant with Medico and promise as follows:

(a) To maintain the books, records, accounting and financial statements of the Subsidiary and all operations related to its current business, in accordance with applicable accounting principles and practices.

(b) To maintain all of the legal requirements that permit the Subsidiary to operate its current business under the federal and provincial laws and regulations of Singapore and comply with all other federal and provincial laws and regulations of Singapore.

(c) Not to incur any debt by the Subsidiary in any event whatsoever, except with the prior written consent of the Board of Directors of Medico.

ARTICLE XIIII

MISCELLANEOUS

Section 14.01. Public Notices. The Parties agree that all notices to third parties and all other publicity concerning the transactions contemplated by this Agreement shall be jointly planned and coordinated and no Party shall act unilaterally in this regard without the prior approval of the others, such approval not to be unreasonably withheld.

Section 14.02. Time. Time shall be of the essence hereof.

Section 14.03. Notices. Any notice or other writing required or permitted to be given hereunder or for the purposes hereof shall be sufficiently given if delivered or faxed to the Party to whom it is given or, if mailed, by prepaid registered mail addressed to such Party at:

if to Purchasers, at:

Eminent Healthcare PTE. LTD.

1 North Bridge Road #19-09

High Street Centre

Singapore 179094

Multi Cate PTE. Ltd.

23 New Industrial Road #07-04

Solstice Business Center

Singapore 536209

if to Medico, at:

187 E. Warm Springs Road, Suite B273

Las Vegas, NV 89119

if to TSG:

The Bristol Office, 2^nd Floor

5 High Street, Westbury on Trym

Bristol, BS9 3BY United Kingdom

or at such other address as the Party to whom such writing is to be given shall have last notified to the Party giving the same in the manner provided in this article. Any notice mailed shall be deemed to have been given and received on the fifth Business Day next following the date of its mailing unless at the time of mailing or within five (5) Business Days thereafter there occurs a postal interruption which could have the effect of delaying the mail in the ordinary and usual course, in which case any notice shall only be effectively given if actually delivered or sent by telecopy. Any notice delivered or faxed to the Party to whom it is addressed shall be deemed to have been given and received on the Business Day next following the day it was delivered or faxed.

Section 14.04. Severability. If a court of competent jurisdiction determines that any one or more of the provisions contained in this Agreement is invalid, illegal or unenforceable in any respect in any jurisdiction, the validity, legality and enforceability of such provision or provisions shall not in any way be affected or impaired thereby in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless in either case as a result of such determination this Agreement would fail in its essential purpose.

Section 14.05. Entire Agreement. This Agreement constitutes the entire agreement between the Parties and supersedes all prior agreements and understandings, oral or written, by and between any of the Parties with respect to the subject matter hereof.

Section 14.06. Further Assurances. The Parties shall with reasonable diligence, do all such things and provide all such reasonable assurances as may be required to consummate the transactions contemplated by this Agreement, and each Party shall provide such further documents or instruments required by the other Party as may be reasonably necessary or desirable to give effect to the purpose of this Agreement and carry out its provisions whether before or after the Closing Date.

Section 14.07. Waiver. Except as provided in this Article, no action taken or inaction pursuant to this Agreement will be deemed to constitute a waiver of compliance with any warranties, conditions or covenants contained in this Agreement and will not operate or be construed as a waiver of any subsequent breach, whether of a similar or dissimilar nature. No waiver of any right under this Agreement shall be binding unless executed in writing by the Party to be bound thereby.

[the remainder of this page is intentionally left blank]

Section 14.08. Counterparts. This Agreement may be executed in as many counterparts as may be necessary or by facsimile and each such counterpart agreement or facsimile so executed shall be deemed to be an original and such counterparts and facsimile copies together shall constitute one and the same instrument and shall be valid and enforceable.

IN WITNESS WHEREOF the Parties hereto have set their hand and seal as of the day and year first above written.

MEDICO INTERNATIONAL INC.,
a Nevada corporation

By:

Name:

Title:

EMINENT HEALTHCARE PTE. LTD.,

a Singapore corporation

By:

Name:

Liew Min Hin

Title:

CEO

MULTI CARE PTE. LTD.,

a Singapore corporation

By:

Name:

Tan Audrey Siok Ling

Title:

CEO

TARGETED SOLUTIONS GLOBAL LIMITED, a

United Kingdom Private limited Company

By:

Name:

Jiang Chun Yan

Title:

Owner

EX-31.1 3 mddt_ex311.htm CERTIFICATION mddt_ex311.htm

Exhibit 31.1

CERTIFICATION

I, JIANG CHUN YAN Chief Executive Officer/President and Chief Financial Officer of MEDICO INTERNATIONAL INC., certify that:

1. I have reviewed this Annual Report on Form 10-K of MEDICO INTERNATIONAL INC.;

2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d- 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure control and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 19, 2017

/s/ Jiang Chun Yan

Jiang Chun Yan, Chief Executive Officer/President and Chief Financial Officer

EX-32.1 4 mddt_ex321.htm CERTIFICATION mddt_ex321.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of MEDICO INTERNATIONAL INC. (the "Company") on Form 10-K for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on or about the date hereof (the "Report"), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 19, 2017

/s/ Jiang Chun Yan

Jiang Chun Yan, Chief Executive Officer/President and Chief Financial Officer

EX-101.INS 5 mddt-20161231.xml XBRL INSTANCE DOCUMENT 0001658432 mddt:SmileMoreHoldingsPte.Ltd.Member 2014-01-31 0001658432 mddt:EminentHealthcarePte.LtdMember mddt:ShareExchangeAgreementMember 2015-09-19 0001658432 mddt:MultiCarePte.LtdMember mddt:ShareExchangeAgreementMember 2015-09-19 0001658432 mddt:EminentHealthcarePte.LtdMember mddt:LiewMinHinMember 2015-09-19 0001658432 mddt:SmileMoreHoldingsPte.Ltd.Member mddt:ShareExchangeAgreementMember 2015-09-01 2015-09-19 0001658432 2015-01-01 2015-12-31 0001658432 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001658432 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001658432 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001658432 us-gaap:CostOfSalesMember 2015-01-01 2015-12-31 0001658432 us-gaap:OperatingExpenseMember 2015-01-01 2015-12-31 0001658432 2015-12-31 0001658432 mddt:SmileMoreHoldingsPte.Ltd.Member 2015-12-31 0001658432 mddt:DentalEquipmentMember 2015-12-31 0001658432 us-gaap:BuildingImprovementsMember 2015-12-31 0001658432 us-gaap:ComputerEquipmentMember 2015-12-31 0001658432 us-gaap:OfficeEquipmentMember 2015-12-31 0001658432 mddt:LabEquipmentMember 2015-12-31 0001658432 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001658432 2016-06-30 0001658432 2016-01-01 2016-12-31 0001658432 us-gaap:ComputerEquipmentMember 2016-01-01 2016-12-31 0001658432 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001658432 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001658432 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001658432 us-gaap:CostOfSalesMember 2016-01-01 2016-12-31 0001658432 us-gaap:OperatingExpenseMember 2016-01-01 2016-12-31 0001658432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001658432 us-gaap:MinimumMember 2016-01-01 2016-12-31 0001658432 us-gaap:MaximumMember 2016-01-01 2016-12-31 0001658432 us-gaap:MinimumMember mddt:DentalEquipmentMember 2016-01-01 2016-12-31 0001658432 us-gaap:MaximumMember mddt:DentalEquipmentMember 2016-01-01 2016-12-31 0001658432 us-gaap:MinimumMember us-gaap:FurnitureAndFixturesMember 2016-01-01 2016-12-31 0001658432 us-gaap:MaximumMember us-gaap:FurnitureAndFixturesMember 2016-01-01 2016-12-31 0001658432 us-gaap:MinimumMember us-gaap:OfficeEquipmentMember 2016-01-01 2016-12-31 0001658432 us-gaap:MaximumMember us-gaap:OfficeEquipmentMember 2016-01-01 2016-12-31 0001658432 us-gaap:EquipmentMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001658432 us-gaap:EquipmentMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001658432 2016-12-31 0001658432 mddt:SmileMoreHoldingsPte.Ltd.Member 2016-12-31 0001658432 mddt:DentalEquipmentMember 2016-12-31 0001658432 us-gaap:BuildingImprovementsMember 2016-12-31 0001658432 us-gaap:ComputerEquipmentMember 2016-12-31 0001658432 us-gaap:OfficeEquipmentMember 2016-12-31 0001658432 mddt:LabEquipmentMember 2016-12-31 0001658432 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001658432 2014-01-20 2016-12-31 0001658432 2014-12-31 0001658432 us-gaap:RetainedEarningsMember 2014-12-31 0001658432 us-gaap:RetainedEarningsMember 2015-12-31 0001658432 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001658432 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001658432 us-gaap:CommonStockMember 2014-12-31 0001658432 us-gaap:CommonStockMember 2015-12-31 0001658432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0001658432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001658432 us-gaap:RetainedEarningsMember 2016-12-31 0001658432 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001658432 us-gaap:CommonStockMember 2016-12-31 0001658432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure Medico International Inc. 0001658432 Yes No --12-31 Smaller Reporting Company No 3697000 0 10-K 2016-12-31 false 2016 FY

316603

287754

111599

263817

416658

193723 222084

84167

113229

927310

1039725

993968

1037656

1921278

2077381

470073

633247

114191

186894

1003296

1150316

1800130

2160082

175343

177083

1975473

2337165

3000

3697

171121

867424

-241690

-1161700

13374

30795

-54195

-259784

-145677

-152982

-241690

171121

907

3000

6398

13374

-1161700

867424

3697

30795

1921278

2077381

69000

212570

187171

0.001

500000000

3000000

3697000

3000000

3697000

4905241

6543428

3781246

5673813

1123995

869615

139930

236711

158781

384287

408413

299956

561167

845684

88473 117415

1356764

1884053

-232769

-1014438

149894

102832

5833

8404

144061

94428

6976

17421

-81732

-902589

-0.06

0.25

1495371

3647486

-88708

-920010

-88708

-920010

907320

3000000

3697000

697000

696303

697

697000

71350 69257 2093 2092680 101864 101864

17421

374037

234000

140000

575689

339000

237000

18769

152841

91405 28361

70557

29062

362877

163174

-133219

72703

272313

-228287

361286

438226

-361286

-438226

697000

581503

147020

294502

223777

287001

620243

6976

17421

205004

-28849

5833

8404

467404

198264

101864 71350

69000

-69000

7057

<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 2: Summary of Significant Accounting Policies <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0.1pt; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Basis of Presentation <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0.1pt; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") on the accrual basis of accounting. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Principles of Consolidation <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. We currently have no investments accounted for using the equity or cost methods of accounting. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Functional Currency <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company's functional currency is the Singapore Dollar and reporting currency is the U.S. dollar. All transactions initiated in Singapore Dollar are translated into U.S. dollars in accordance with Accounting Standards Codification (“ASC”) 830-30, "Translation of Financial Statements," as follows: <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" width="3%">i)</td> <td valign="top">Assets and liabilities at the rate of exchange in effect at the balance sheet date.</td> </tr> <tr> <td valign="top" width="3%">ii)</td> <td valign="top">Equity at historical rates.</td> </tr> <tr> <td valign="top" width="3%">iii)</td> <td valign="top">Revenue and expense items at the average rate of exchange prevailing during the period.</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Adjustments arising from such translations are included in accumulated other comprehensive gain in stockholders’ deficit. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Use of Estimates <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements in conformity with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">   <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Cash and Cash Equivalents <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> Cash and cash equivalents consists of cash and all highly liquid investments with a maturity of three months or less. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company maintains its cash accounts primarily with banks located in Singapore and they are all denominated in Singapore dollar. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">   <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accounts Receivables <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accounts receivable consist primarily of receivables from provided services. Management determines the allowance for doubtful accounts based on customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. On a continuing basis, management analyzes delinquent receivables, and once these receivables are determined to be uncollectible, they are written off against an existing allowance account. As of December 31, 2016 and 2015, the Company has determined that an allowance for doubtful accounts is not necessary as all accounts are considered fully collectible. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Inventory <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Inventory is stated at the lower of cost or market. Cost is computed using weighted average cost, which approximates actual cost, on a first-in, first-out basis. Inventory on hand is evaluated on an on-going basis to determine if any items are obsolete or in excess of future needs. Items determined to be obsolete are reserved for. The Company provides for the possible inability to sell its inventory by providing an excess inventory reserve. As of December 31, 2016 and 2015 the Company determined that no reserve was required. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and Equipment <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and equipment are stated at cost and are depreciated over their estimated useful lives using the straight-line method. Expenditures for ordinary maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and accumulated depreciation are eliminated from the account and any gain or loss is reflected on the consolidated statements of operations. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Estimated useful lives for computers are 1 ~ 3 years and useful lives for dental equipment, furniture and fittings, office equipment and lab equipment are 3 ~ 5 years. Renovations are included at the lessor of useful life or the life of the lease. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Impairment or Disposal of Long-Lived Assets <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates its long-lived assets whenever significant events or changes in circumstances occur that indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted future net cash flows from the operations to which the assets relate, based on management’s best estimates using appropriate assumptions and projections at the time, to the carrying amount of the assets. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss is recognized equal to the amount by which the carrying amount exceeds the estimated fair value of the asset. No such impairment was indicated at December 31, 2016 and 2015. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair Value of Financial Instruments Estimates <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> The Company’s financial instruments including accounts receivable, accounts payable, accrued and other payables and due to related parties are carried at cost, which approximates fair value due to the short-term maturity of these instruments. The recorded value of the Company’s long-term debt approximates its fair value as it bears interest at a floating rate. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Concentrations of Credit Risk <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially subject the Company to a significant concentration of credit risk include cash. At times, the Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management monitors the credit rating and concentration of risk with these financial institutions on a continuing basis to mitigate risk. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" >Taxes Collected and Remitted to Governmental Authorities <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company reports taxes collected from customers, which are primarily goods and service tax, on a net basis. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Revenue Recognition <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Revenues are recognized when services are rendered, amounts are reliably measurable, and collectability is assured. Revenue is presented, net of goods and services tax, rebates and discounts. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Advertising <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Advertising costs are expensed as incurred. Advertising costs totaled $53,917 and $13,536 for the years ended December 31, 2016 and 2015, respectively. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Income Taxes <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Current income tax liabilities for current and prior years are recognized at the amounts expected to be paid to the tax authorities, using the tax rates (and tax laws) that have been enacted or substantially enacted by the balance sheet date. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Deferred income tax assets/liabilities are recognized for all deductible/taxable temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements except when the deferred income tax assets/liabilities arise from the initial recognition of an asset or liability in a transaction that is not a business combination and at the time of the transaction, affects neither accounting nor taxable profit or loss. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Deferred income tax assets and liabilities are measured at: <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0.5in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 45px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">(i) the tax rates that are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled, based on tax rates (and tax laws) that have been enacted or substantially enacted by the balance sheet date; and <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 45px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 45px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">(ii) the tax consequence that would follow from the manner in which the Company expects, at the balance sheet date, to recover or settle the carrying amounts of its assets and liabilities. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Current and deferred income taxes are recognized as income or expenses in the consolidated statements of operations. <p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Recent Accounting Pronouncements <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In December 2016, the Financial Accounting Standards Board (FASB) has issued ASU No. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers.” The amendments affect narrow aspects of the guidance issued in ASU 2014-09 including Loan Guarantee Fees, Contract Costs, Provisions for Losses on Construction-Type and Production-Type Contracts, Disclosure of Remaining Performance Obligations, Disclosure of Prior Period Performance Obligations, Contract Modifications, Contract Asset vs. Receivable, Refund Liability, Advertising Costs, Fixed Odds Wagering Contracts in the Casino Industry, and Costs Capitalized for Advisors to Private Funds and Public Funds. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements for FASB ASC Topic 606. Public entities should apply Topic 606 (and related amendments) for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein. The Company is currently evaluating the potential impact that the adoption of this ASU may have on its consolidated financial statements. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Management has considered all recent accounting pronouncements issued. The Company's management believes that these other recent pronouncements will not have a material effect on the Company's consolidated financial statements.

<p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 4: Property and Equipment <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2016 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2015 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Dental equipment </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">1,057,544</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">835,949</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Renovation </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">755,217</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">525,341</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Computer </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">68,003</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">60,190</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Office equipment </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">19,258</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">20,539</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Lab equipment </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">6,679</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">6,135</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Furniture and fittings </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">3,218</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">530</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td>   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">1,909,919</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">1,448,684</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Less accumulated depreciation </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(872,263</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(454,716</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td>   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">1,037,656</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">993,968</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table> <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Depreciation expense of approximately $576,000 and $374,000 was recorded by the Company for the years ended December 31, 2016 and 2015, respectively. Approximately $339,000 and $234,000 is included in the cost of services and approximately $237,000 and $140,000 is included in operating expenses on the Company’s consolidated statements of operations for the years ended December 31, 2016 and 2015, respectively.

<p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 8: Income Taxes <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for income taxes in accordance with the provisions of FASB ASC 740, Accounting for Uncertainty in Income Taxes. The Company files income tax returns in Singapore and there are currently no federal income tax examinations underway. The Company’s tax year of 2014 and forward are subject to examination by federal taxing authorities for at least five years. <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for income taxes using an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The provision for income taxes includes: <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> 2016 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> 2015 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Taxes – current </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">-</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">-</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Taxes – deferred </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">-</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">-</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Income tax expenses </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table> <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is subject to taxation in the United States and Singapore. <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The provision for income taxes differs from the amounts which would be provided by applying the statutory income tax rate of 17% in Singapore and 34% in the United States to the net income (loss) before provision for income taxes for the following reasons: <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> 2016 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> 2015 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Computed at the statutory rate </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">312,803</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">30,161</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Difference in rates in Singapore </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(139,261</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(5,879</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Non-deductible expenses </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">-</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">-</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Change in valuation allowance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(173,542</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(24,282</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Actual tax expense </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table> <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Following are the details of deferred tax assets and its valuation allowance: <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2016 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2015 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> </tr> <tr> <td valign="top"> Deferred tax assets </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%" colspan="2">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%" colspan="2">   </td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Net operating loss carry forwards </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">1,161,700</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">241,690</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Deferred tax asset before valuation allowance </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="9%">223,831</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="9%">50,289</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Valuation allowance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">   </td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Beginning balance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(50,289</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(26,007</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Changes during the period </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">(173,542</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">(24,282</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Ending balance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(223,831</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(50,289</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td>   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table> <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The related deferred tax benefit on the above unutilized tax losses has a full valuation allowance not recognized against it as there is no certainty of its realization. Management has evaluated tax positions in accordance with ASC 740 and has not identified any significant tax positions, other than those disclosed. <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has yet to file its tax return with the Inland Revenue Authority of Singapore for the year of assessment of 2016. <p style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Due to the change in ownership provisions of the income tax laws of United States of America, net operating loss carry forwards of approximately $1,161,700, which expire commencing in fiscal 2035, for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.

0.17

0.34

1161700

<p align="justify" style="margin: 0px 0px 0px 0.1pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Basis of Presentation <p align="justify" style="margin: 0px 0px 0px 0.1pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="margin: 0px 0px 0px 0in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") on the accrual basis of accounting.

<table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2016 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2015 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Dental equipment </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">1,057,544</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">835,949</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Renovation </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">755,217</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">525,341</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Computer </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">68,003</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">60,190</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Office equipment </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">19,258</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">20,539</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Lab equipment </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">6,679</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">6,135</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Furniture and fittings </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">3,218</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">530</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td>   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">1,909,919</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">1,448,684</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Less accumulated depreciation </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(872,263</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(454,716</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td>   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">1,037,656</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">993,968</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table>

<table align="center" style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr bgcolor="#cceeff"> <td valign="top"> 2017 </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">196,782</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> 2018 </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">118,886</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2019 </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">69,589</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Total </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">385,257</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Amount representing interest payments </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">(21,003</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Present value of future minimum payments </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">364,254</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Capital lease obligation, current portion </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">187,171</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Capital lease obligation, long-term portion </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">177,083</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table>

<table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2016 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> <td valign="bottom">   </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> December 31, 2015 </td> <td style="padding-bottom: 1px;" valign="bottom">   </td> </tr> <tr> <td valign="top"> Deferred tax assets </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%" colspan="2">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%" colspan="2">   </td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Net operating loss carry forwards </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">1,161,700</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">$</td> <td align="right" valign="bottom" width="9%">241,690</td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Deferred tax asset before valuation allowance </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="9%">223,831</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 1px; border-top-style: solid; border-bottom-style: solid;" valign="bottom" width="9%">50,289</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Valuation allowance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">   </td> <td valign="bottom" width="1%">   </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Beginning balance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(50,289</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(26,007</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Changes during the period </td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">(173,542</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">   </td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">(24,282</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> Ending balance </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(223,831</td> <td valign="bottom" width="1%">)</td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td align="right" valign="bottom" width="9%">(50,289</td> <td valign="bottom" width="1%">)</td> </tr> <tr bgcolor="#cceeff"> <td>   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%">   </td> <td style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="1%">$</td> <td align="right" style="border-top-color: currentcolor; border-bottom-color: currentcolor; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%">   </td> </tr> </table>

6 3 2 1

3000000

0.30

0.70

1.00

1 ~ 3 years

P3Y

P5Y

P3Y

P5Y

P3Y

P5Y

P3Y

P5Y

13536

53917

1120357

1448684

835949

525341

60190

20539

6135

530

1909919

1057544

755217

68003

19258

6679

3218

454716

872263

196782

118886

69589

385257

21003

364254

P3Y P5Y 0.03 0.07

790578

457567

110592

1358737

581503 147020

30161

312803

-5879

-139261

-24282

-173542

241690

1161700

50289

223831

50289

223831

26007

2454

-18967

2454

1.00

mddt P5Y mddt:Clinic 0001658432us-gaap:AccumulatedOtherComprehensiveIncomeMember2015-01-012015-12-31

6976

iso4217:SGD 0001658432mddt:LeaseAgreementMember us-gaap:SubsequentEventMember 2017-02-14

948616

mddt:Agreement 4 0001658432us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMember us-gaap:SubsequentEventMember 2017-02-14 600000

655494

0001658432us-gaap:MajorityShareholderMemberus-gaap:MajorityOwnedSubsidiaryUnconsolidatedMemberus-gaap:SubsequentEventMember2017-02-14 3000000 0001658432us-gaap:MajorityOwnedSubsidiaryUnconsolidatedMemberus-gaap:SubsequentEventMember2017-06-05 1 0001658432mddt:StockPurchaseAgreementMember us-gaap:ChiefFinancialOfficerMember mddt:EminentHealthcarePteLtdMember us-gaap:SubsequentEventMember 2017-06-05 1 0001658432us-gaap:MajorityShareholderMembermddt:TargetedSolutionsGlobalLimitedMemberus-gaap:SubsequentEventMember2017-06-05 200000 00016584322017-06-12

EX-101.SCH 6 mddt-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Nature of Operations link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Capital Leases link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Related Parties Transactions link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Common Stock link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Capital Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Nature of Operations (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Going Concern (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Property and Equipment (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Capital Leases (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Capital Leases (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Related Parties Transactions (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Common Stock (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Income Taxes (Details 1) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Income Taxes (Details 2) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Income Taxes (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Commitments and Contingencies (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Subsequent Events (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 mddt-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mddt-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mddt-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Entity Current Reporting Status Entity Voluntary Filers Current Fiscal Year End Date Entity Filer Category Entity Well-known Seasoned Issuer Entity Common Stock, Shares Outstanding Entity Public Float Document Type Document Period End Date Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Accounts Receivable, Net, Current Accounts receivable Other Receivables, Net, Current Other receivables Prepaid Expenses And Deposits Prepaid expenses and deposits Represents amount related to prepaid expenses and deposits. Inventory, Net Inventory Assets, Current Total Current Assets Total Current Assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Assets TOTAL ASSETS TOTAL ASSETS Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current Liabilities Accounts Payable, Current Accounts payable Other Accrued Liabilities, Current Accrued and other payables Due to Related Parties, Current Due to related parties Deferred Revenue, Current Deferred revenue Capital Lease Obligations, Current Capital lease obligation, current portion Capital lease obligations - current Liabilities, Current Total Current Liabilities Total Current Liabilities Capital Lease Obligations, Noncurrent Capital lease obligations Capital lease obligation, long-term portion Liabilities TOTAL LIABILITIES TOTAL LIABILITIES Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (NOTE 9) Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' DEFICIT Common Stock, Value, Issued Common stock, $0.001 par value; 500,000,000 shares authorized, 3,697,000 and 3,000,000 shares issued and outstanding, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive gain Stockholders' Equity Attributable to Parent, Total TOTAL STOCKHOLDERS' DEFICIT Balance Balance Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares, outstanding Income Statement [Abstract] Revenues DENTAL SERVICE REVENUE, NET Cost of Services COST OF SERVICES Gross Profit GROSS PROFIT GROSS PROFIT Operating Expenses [Abstract] OPERATING EXPENSES Operating Leases, Rent Expense Rent expenses Rental General and Administrative Expense General and administrative Professional Fees Professional fees Depreciation, Nonproduction Depreciation Staff Costs Staff costs Represents the amount related to staff cost. Operating Expenses Total Operating Expenses Operating Income (Loss) LOSS FROM OPERATIONS LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] OTHER INCOME/(EXPENSE) Other Nonoperating Income (Expense) Other income Interest Expense Interest expense Interest expense Nonoperating Income (Expense) Total other income/(expense) TOTAL OTHER INCOME/(EXPENSE) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest LOSS BEFORE INCOME TAXES LOSS BEFORE INCOME TAXES Income Tax Expense (Benefit) Provision for income taxes Actual tax expense Net Income (Loss) Attributable to Parent Net loss Net loss NET LOSS Other Comprehensive Income (Loss), Net of Tax [Abstract] OTHER COMPREHENSIVE LOSS Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustments Other Comprehensive Income (Loss), Net of Tax TOTAL COMPREHENSIVE LOSS TOTAL COMPREHENSIVE LOSS Earnings Per Share, Basic and Diluted Basic and Diluted Loss per Common Share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and Diluted Weighted Average Common Shares Outstanding (in shares) Statement of Stockholders' Equity [Abstract] Statement [Table] Equity Components [Axis] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Equity Component [Domain] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments To Additional Paid In Capital Stock Issued In Exchange Adjustment on shares exchange Represents the amount related to adjustment on shares exchange. Adjustments To Additional Paid In Capital Stock Issued In Exchange Shares Adjustment on shares exchange (in shares) Represents the shares related to adjustment on shares exchange. Adjustments To Additional Paid In Capital Loans Forgiven By Shareholder Value Loans forgiven by shareholder recorded as additional paid in capital Loans forgiven by shareholder Represents the amount related to loans forgiven by shareholder. Stock Issued During Period, Value, New Issues Issuance of shares Value of shares issued in connection with registration statement Stock Issued During Period, Shares, New Issues Number of shares issued in connection with registration statement Issuance of shares (in shares) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash from operating activities: Provision for Doubtful Accounts Bad debt Depreciation Depreciation expense Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of equipment Loss on disposal of equipment Increase (Decrease) in Operating Assets [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Accounts receivable Increase (Decrease) in Other Receivables Other receivables Increase Decrease In Prepaid Expenses And Deposits Prepaid expenses and deposits Represents the amount related to prepaid expenses and deposits. Prepaid expenses and deposits Increase (Decrease) in Inventories Inventory Inventory Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accrued and other payables Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from Issuance of Common Stock Issuance of shares Proceeds from issuance of common stock Proceeds from Related Party Debt Advances received from officers Loans from related parties Repayments of Long-term Capital Lease Obligations Repayment of capital lease obligations Repayment of capital lease obligations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Effect of Exchange Rate on Cash and Cash Equivalents Effects on changes in foreign exchange rate Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Disclosures Interest Paid Cash paid for interest Income Taxes Paid Cash paid for income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-Cash Investing and Financing Activity: Capital Lease Obligations Incurred Equipment acquired under capital lease obligations Loans Forgiven By Shareholder Loans forgiven by shareholder Represents loans forgiven by shareholder. Share Exchange Share exchange Represents the amount related to share exchange. Nature Of Operations [Abstract] Nature of Operations [Text Block] Nature of Operations Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Going Concern [Abstract] Substantial Doubt about Going Concern [Text Block] Going Concern Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Leases, Capital [Abstract] Capital Leases in Financial Statements of Lessee Disclosure [Text Block] Capital Leases Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Parties Transactions Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Common Stock Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Principles of Consolidation Foreign Currency Transactions and Translations Policy [Policy Text Block] Functional Currency Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Receivables, Policy [Policy Text Block] Accounts Receivables Inventory, Policy [Policy Text Block] Inventories Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Estimates Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk Regulatory Income Taxes, Policy [Policy Text Block] Taxes Collected and Remitted to Governmental Authorities Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Advertising Costs, Policy [Policy Text Block] Advertising Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of future minimum lease payments under finance leases Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of provision for income taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of provision for income taxes differs from the amounts provided by applying the statutory income tax Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax assets and its valuation Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments Schedule of future aggregate minimum lease payments Nature Of Operations [Table] Table of nature of operations. Legal Entity [Axis] Entity [Domain] Smile More Holdings Pte. Ltd. [Member] Smile Central Name of the legal entity. Eminent Healthcare Pte. Ltd [Member] Eminent Healthcare Pte. Ltd. Name of the legal entity. Multi Care Pte. Ltd [Member] Multi Care Pte. Ltd. Name of the legal entity. Title of Individual [Axis] Relationship to Entity [Domain] Liew Min Hin [Member] Liew Min Hin Name of the CFO. Agreement [Axis] Represents agreement between the parties. Agreement [Domain] Represents agreement between the parties. Share Exchange Agreement [Member] Share Exchange Agreement Represents Share Exchange Agreement. Nature Of Operations [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Sale of Stock, Number of Shares Issued in Transaction Number of common stock issued Equity Method Investment, Ownership Percentage Ownership percentage Number Of Dental Clinics Owned Number of dental clinics owned in Singapore Represents number of dental clinics owned. Number Of Dental Clinics Launched Number of dental clinics launched Represents number of dental clinics launched. Number Of Additional Dental Clinics Opened Number of additional dental clinics opened Represents number of additional dental clinics opened. Summary Of Significant Accounting Policies [Table] Table of summary of significant accounting policies. Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer Dental Equipment [Member] Dental Equipment Dental equipment Represents dental equipment. Furniture and Fixtures [Member] Furniture and Fittings Furniture and fittings Office Equipment [Member] Office Equipment Office equipment Equipment [Member] Lab equipment Building Improvements [Member] Renovation Range [Axis] EX-101.PRE 10 mddt-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 mddt_10kimg1.jpg begin 644 mddt_10kimg1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2016	Jun. 12, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Medico International Inc.
Entity Central Index Key	0001658432
Trading Symbol	mddt
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		3,697,000
Entity Public Float			$ 0
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 287,754	$ 316,603
Accounts receivable	416,658	263,817
Other receivables		69,000
Prepaid expenses and deposits	222,084	193,723
Inventory	113,229	84,167
Total Current Assets	1,039,725	927,310
Property and equipment, net	1,037,656	993,968
TOTAL ASSETS	2,077,381	1,921,278
Current Liabilities
Accounts payable	633,247	470,073
Accrued and other payables	186,894	114,191
Due to related parties	1,150,316	1,003,296
Deferred revenue	2,454
Capital lease obligations - current	187,171	212,570
Total Current Liabilities	2,160,082	1,800,130
Capital lease obligations	177,083	175,343
TOTAL LIABILITIES	2,337,165	1,975,473
COMMITMENTS AND CONTINGENCIES (NOTE 9)
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value; 500,000,000 shares authorized, 3,697,000 and 3,000,000 shares issued and outstanding, respectively	3,697	3,000
Additional paid-in capital	867,424	171,121
Accumulated deficit	(1,161,700)	(241,690)
Accumulated other comprehensive gain	30,795	13,374
TOTAL STOCKHOLDERS' DEFICIT	(259,784)	(54,195)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 2,077,381	$ 1,921,278

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	3,697,000	3,000,000
Common stock, shares, outstanding	3,697,000	3,000,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
DENTAL SERVICE REVENUE, NET	$ 6,543,428	$ 4,905,241
COST OF SERVICES	5,673,813	3,781,246
GROSS PROFIT	869,615	1,123,995
OPERATING EXPENSES
Rental	845,684	561,167
General and administrative	384,287	158,781
Professional fees	299,956	408,413
Depreciation	236,711	139,930
Staff costs	117,415	88,473
Total Operating Expenses	1,884,053	1,356,764
LOSS FROM OPERATIONS	(1,014,438)	(232,769)
OTHER INCOME/(EXPENSE)
Other income	102,832	149,894
Interest expense	(8,404)	(5,833)
TOTAL OTHER INCOME/(EXPENSE)	94,428	144,061
LOSS BEFORE INCOME TAXES	(920,010)	(88,708)
Provision for income taxes
NET LOSS	(920,010)	(88,708)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	17,421	6,976
TOTAL COMPREHENSIVE LOSS	$ (902,589)	$ (81,732)
Basic and Diluted Loss per Common Share (in dollars per share)	$ 0.25	$ (0.06)
Basic and Diluted Weighted Average Common Shares Outstanding (in shares)	3,647,486	1,495,371

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2014	$ 907		$ (152,982)	$ 6,398	$ (145,677)
Balance (in shares) at Dec. 31, 2014	907,320
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adjustment on shares exchange	$ 2,093	69,257			71,350
Adjustment on shares exchange (in shares)	2,092,680
Loans forgiven by shareholder		101,864			101,864
Net loss			(88,708)		(88,708)
Foreign currency translation adjustments				6,976	6,976
Balance at Dec. 31, 2015	$ 3,000	171,121	(241,690)	13,374	(54,195)
Balance (in shares) at Dec. 31, 2015	3,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adjustment on shares exchange
Issuance of shares	$ 697	696,303			$ 697,000
Issuance of shares (in shares)	697,000				697,000
Net loss			(920,010)		$ (920,010)
Foreign currency translation adjustments				17,421	17,421
Balance at Dec. 31, 2016	$ 3,697	$ 867,424	$ (1,161,700)	$ 30,795	$ (259,784)
Balance (in shares) at Dec. 31, 2016	3,697,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (920,010)	$ (88,708)
Adjustments to reconcile net loss to net cash from operating activities:
Bad debt		7,057
Depreciation	575,689	374,037
Loss on disposal of equipment	18,967
Changes in operating assets and liabilities:
Accounts receivable	(152,841)	(18,769)
Other receivables	69,000	(69,000)
Prepaid expenses and deposits	(28,361)	(91,405)
Inventory	(29,062)	(70,557)
Accounts payable	163,174	362,877
Accrued and other payables	72,703	(133,219)
Deferred revenue	2,454
Net cash (used in) provided by operating activities	(228,287)	272,313
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(438,226)	(361,286)
Net cash used in investing activities	(438,226)	(361,286)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares	697,000
Loans from related parties	147,020	581,503
Repayment of capital lease obligations	(223,777)	(294,502)
Net cash provided by financing activities	620,243	287,001
Effects on changes in foreign exchange rate	17,421	6,976
Net increase in cash and cash equivalents	(28,849)	205,004
Cash and cash equivalents - beginning of period	316,603	111,599
Cash and cash equivalents - end of period	287,754	316,603
Supplemental Cash Flow Disclosures
Cash paid for interest	8,404	5,833
Cash paid for income taxes
Non-Cash Investing and Financing Activity:
Equipment acquired under capital lease obligations	$ 198,264	467,404
Loans forgiven by shareholder		101,864
Share exchange		$ 71,350

XML 18 R7.htm IDEA: XBRL DOCUMENT

Nature of Operations

12 Months Ended

Dec. 31, 2016

Nature Of Operations [Abstract]

Nature of Operations

Note 1: Nature of Operations

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") on the accrual basis of accounting.

Principles of Consolidation

Functional Currency

i)	Assets and liabilities at the rate of exchange in effect at the balance sheet date.
ii)	Equity at historical rates.
iii)	Revenue and expense items at the average rate of exchange prevailing during the period.

Adjustments arising from such translations are included in accumulated other comprehensive gain in stockholders’ deficit.

Use of Estimates

Cash and Cash Equivalents

Cash and cash equivalents consists of cash and all highly liquid investments with a maturity of three months or less.

The Company maintains its cash accounts primarily with banks located in Singapore and they are all denominated in Singapore dollar.

Accounts Receivables

Inventory

Property and Equipment

Impairment or Disposal of Long-Lived Assets

Fair Value of Financial Instruments Estimates

Concentrations of Credit Risk

Taxes Collected and Remitted to Governmental Authorities

The Company reports taxes collected from customers, which are primarily goods and service tax, on a net basis.

Revenue Recognition

Revenues are recognized when services are rendered, amounts are reliably measurable, and collectability is assured. Revenue is presented, net of goods and services tax, rebates and discounts.

Advertising

Advertising costs are expensed as incurred. Advertising costs totaled $53,917 and $13,536 for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Deferred income tax assets and liabilities are measured at:

(ii) the tax consequence that would follow from the manner in which the Company expects, at the balance sheet date, to recover or settle the carrying amounts of its assets and liabilities.

Current and deferred income taxes are recognized as income or expenses in the consolidated statements of operations.

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Going Concern

12 Months Ended

Dec. 31, 2016

Going Concern [Abstract]

Going Concern

Note 3: Going Concern

Management's plans include raising capital through the equity markets to fund operations and eventually, generating profit through its business; however, there can be no assurance that the Company will be successful in such activities. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Property and Equipment

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 4: Property and Equipment

	December 31, 2016			December 31, 2015
Dental equipment	$	1,057,544		$	835,949
Renovation		755,217			525,341
Computer		68,003			60,190
Office equipment		19,258			20,539
Lab equipment		6,679			6,135
Furniture and fittings		3,218			530
		1,909,919			1,448,684
Less accumulated depreciation		(872,263	)		(454,716	)
	$	1,037,656		$	993,968

XML 22 R11.htm IDEA: XBRL DOCUMENT

Capital Leases

12 Months Ended

Dec. 31, 2016

Leases, Capital [Abstract]

Capital Leases

Note 5: Capital Leases

The Company leases dental equipment under non-cancellable capital lease arrangements. The terms of those capital leases vary from 3 to 5 years and annual interest rates vary from 3% to 7%.

As of December 31, 2016, the future minimum lease payments under finance leases are as follows:

2017	$	196,782
2018		118,886
2019		69,589
Total		385,257
Amount representing interest payments		(21,003	)
Present value of future minimum payments		364,254
Capital lease obligation, current portion		187,171
Capital lease obligation, long-term portion	$	177,083

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Parties Transactions

12 Months Ended

Dec. 31, 2016

Related Parties Transactions

Note 6: Related Parties Transactions

During the year ended December 31, 2015, one of the Company’s officers forgave $101,864 of expenses paid on behalf of the Company, which was recorded as additional paid in capital.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Common Stock

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Common Stock

Note 7: Common Stock

During the year ended December 31, 2016, the Company issued 697,000 shares at $1.00 per share in connection with its registration statement resulting in proceeds of $697,000.

As of December 31, 2016 and 2015, 3,697,000 and 3,000,000 shares of common stock were issued and outstanding, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 8: Income Taxes

The provision for income taxes includes:

	2016		2015
Taxes – current	$	-	$	-
Taxes – deferred		-		-
Income tax expenses	$	-	$	-

The Company is subject to taxation in the United States and Singapore.

	2016			2015
Computed at the statutory rate	$	312,803		$	30,161
Difference in rates in Singapore		(139,261	)		(5,879	)
Non-deductible expenses		-			-
Change in valuation allowance		(173,542	)		(24,282	)
Actual tax expense	$	-		$	-

Following are the details of deferred tax assets and its valuation allowance:

	December 31, 2016			December 31, 2015
Deferred tax assets
Net operating loss carry forwards	$	1,161,700		$	241,690
Deferred tax asset before valuation allowance		223,831			50,289
Valuation allowance
Beginning balance		(50,289	)		(26,007	)
Changes during the period		(173,542	)		(24,282	)
Ending balance		(223,831	)		(50,289	)
	$	-		$	-

The Company has yet to file its tax return with the Inland Revenue Authority of Singapore for the year of assessment of 2016.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9: Commitments and Contingencies

As of December 31, 2016, the approximate future aggregate minimum lease payments under the non-cancellable operating leases were as follows:

2017	$	790,578
2018		457,567
2019		110,592
	$	1,358,737

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

12 Months Ended

Dec. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

Note 10: Subsequent Events

Due to the continued consolidated losses experience by the Company as the result of the losses of the Company’s wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), the Board of Directors of the Company believed it was in the best interests of the Company and its shareholders to dispose of Smile Central. In addition, the Company had provided Smile Central with over $600,000 in intra-company loans (the “Intra-Company Loan”).

In addition, under the Share Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") on the accrual basis of accounting.

Principles of Consolidation

Principles of Consolidation

Functional Currency

Functional Currency

i)	Assets and liabilities at the rate of exchange in effect at the balance sheet date.
ii)	Equity at historical rates.
iii)	Revenue and expense items at the average rate of exchange prevailing during the period.

Adjustments arising from such translations are included in accumulated other comprehensive gain in stockholders’ deficit.

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents consists of cash and all highly liquid investments with a maturity of three months or less.

The Company maintains its cash accounts primarily with banks located in Singapore and they are all denominated in Singapore dollar.

Accounts Receivables

Accounts Receivables

Inventories

Inventory

Property and Equipment

Property and Equipment

Impairment or Disposal of Long-Lived Assets

Impairment or Disposal of Long-Lived Assets

Fair Value of Financial Instruments Estimates

Fair Value of Financial Instruments Estimates

Concentrations of Credit Risk

Concentrations of Credit Risk

Taxes Collected and Remitted to Governmental Authorities

Taxes Collected and Remitted to Governmental Authorities

The Company reports taxes collected from customers, which are primarily goods and service tax, on a net basis.

Revenue Recognition

Revenue Recognition

Revenues are recognized when services are rendered, amounts are reliably measurable, and collectability is assured. Revenue is presented, net of goods and services tax, rebates and discounts.

Advertising

Advertising

Advertising costs are expensed as incurred. Advertising costs totaled $53,917 and $13,536 for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

Income Taxes

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Deferred income tax assets and liabilities are measured at:

(ii) the tax consequence that would follow from the manner in which the Company expects, at the balance sheet date, to recover or settle the carrying amounts of its assets and liabilities.

Current and deferred income taxes are recognized as income or expenses in the consolidated statements of operations.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 29 R18.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	December 31, 2016			December 31, 2015
Dental equipment	$	1,057,544		$	835,949
Renovation		755,217			525,341
Computer		68,003			60,190
Office equipment		19,258			20,539
Lab equipment		6,679			6,135
Furniture and fittings		3,218			530
		1,909,919			1,448,684
Less accumulated depreciation		(872,263	)		(454,716	)
	$	1,037,656		$	993,968

XML 30 R19.htm IDEA: XBRL DOCUMENT

Capital Leases (Tables)

12 Months Ended

Dec. 31, 2016

Leases, Capital [Abstract]

Schedule of future minimum lease payments under finance leases

2017	$	196,782
2018		118,886
2019		69,589
Total		385,257
Amount representing interest payments		(21,003	)
Present value of future minimum payments		364,254
Capital lease obligation, current portion		187,171
Capital lease obligation, long-term portion	$	177,083

XML 31 R20.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of provision for income taxes

	2016		2015
Taxes – current	$	-	$	-
Taxes – deferred		-		-
Income tax expenses	$	-	$	-

Schedule of provision for income taxes differs from the amounts provided by applying the statutory income tax

	2016			2015
Computed at the statutory rate	$	312,803		$	30,161
Difference in rates in Singapore		(139,261	)		(5,879	)
Non-deductible expenses		-			-
Change in valuation allowance		(173,542	)		(24,282	)
Actual tax expense	$	-		$	-

Schedule of deferred tax assets and its valuation

	December 31, 2016			December 31, 2015
Deferred tax assets
Net operating loss carry forwards	$	1,161,700		$	241,690
Deferred tax asset before valuation allowance		223,831			50,289
Valuation allowance
Beginning balance		(50,289	)		(26,007	)
Changes during the period		(173,542	)		(24,282	)
Ending balance		(223,831	)		(50,289	)
	$	-		$	-

XML 32 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of future aggregate minimum lease payments

2017	$	790,578
2018		457,567
2019		110,592
	$	1,358,737

XML 33 R22.htm IDEA: XBRL DOCUMENT

Nature of Operations (Detail Textuals)	1 Months Ended
Nature of Operations (Detail Textuals)	Sep. 19, 2015 shares	Dec. 31, 2016 Clinic	Dec. 31, 2015 Clinic	Jan. 31, 2014 Clinic
Smile Central
Nature Of Operations [Line Items]
Number of dental clinics owned in Singapore			6
Number of dental clinics launched				3
Number of additional dental clinics opened		1	2
Smile Central \| Share Exchange Agreement
Nature Of Operations [Line Items]
Number of common stock issued \| shares	3,000,000
Eminent Healthcare Pte. Ltd. \| Share Exchange Agreement
Nature Of Operations [Line Items]
Ownership percentage	30.00%
Eminent Healthcare Pte. Ltd. \| Liew Min Hin
Nature Of Operations [Line Items]
Ownership percentage	100.00%
Multi Care Pte. Ltd. \| Share Exchange Agreement
Nature Of Operations [Line Items]
Ownership percentage	70.00%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Detail Textuals)	12 Months Ended
	Dec. 31, 2016
Computer
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	1 ~ 3 years
Dental Equipment \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life	3 years
Dental Equipment \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life	5 years
Furniture and Fittings \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life	3 years
Furniture and Fittings \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life	5 years
Office Equipment \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life	3 years
Office Equipment \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life	5 years
Lab equipment \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Useful life	3 years
Lab equipment \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Useful life	5 years

XML 35 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Detail Textuals 1) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Advertising costs	$ 53,917	$ 13,536

XML 36 R25.htm IDEA: XBRL DOCUMENT

Going Concern (Detail Textuals) - USD ($)	35 Months Ended
Going Concern (Detail Textuals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Going Concern [Abstract]
Accumulated deficit	$ (1,161,700)	$ (241,690)
Working capital deficiency	$ (1,120,357)

XML 37 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,909,919	$ 1,448,684
Less accumulated depreciation	(872,263)	(454,716)
Property and equipment, net	1,037,656	993,968
Renovation
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	755,217	525,341
Computer
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	68,003	60,190
Office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	19,258	20,539
Furniture and fittings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,218	530
Dental equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,057,544	835,949
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 6,679	$ 6,135

XML 38 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment (Detail Textuals) - USD ($)	12 Months Ended
Property and Equipment (Detail Textuals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 575,689	$ 374,037
Cost of services
Property, Plant and Equipment [Line Items]
Depreciation expense	339,000	234,000
Operating expenses
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 237,000	$ 140,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Capital Leases (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Leases, Capital [Abstract]
2017	$ 196,782
2018	118,886
2019	69,589
Total	385,257
Amount representing interest payments	(21,003)
Present value of future minimum payments	364,254
Capital lease obligation, current portion	187,171	$ 212,570
Capital lease obligation, long-term portion	$ 177,083	$ 175,343

XML 40 R29.htm IDEA: XBRL DOCUMENT

Capital Leases (Detail Textuals)	12 Months Ended
Capital Leases (Detail Textuals)	Dec. 31, 2016
Minimum
Schedule Of Capital Leases [Line Items]
Capital leases, term of contract	3 years
Capital leases, annual interest rate	3.00%
Maximum
Schedule Of Capital Leases [Line Items]
Capital leases, term of contract	5 years
Capital leases, annual interest rate	7.00%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Related Parties Transactions (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Advances received from officers	$ 147,020	$ 581,503
Due to related parties	$ 1,150,316	1,003,296
Loans forgiven by shareholder recorded as additional paid in capital		$ 101,864

XML 42 R31.htm IDEA: XBRL DOCUMENT

Common Stock (Details) - USD ($)	12 Months Ended
Common Stock (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Issuance of shares (in shares)	697,000
Stock issued price per share	$ 1.00
Proceeds from issuance of common stock	$ 697,000
Common stock, shares issued	3,697,000	3,000,000
Common stock, shares, outstanding	3,697,000	3,000,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Taxes - current
Taxes - deferred
Actual tax expense

XML 44 R33.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 1) - USD ($)	12 Months Ended
Income Taxes (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Computed at the statutory rate	$ 312,803	$ 30,161
Difference in rates in Singapore	(139,261)	(5,879)
Non-deductible expenses
Change in valuation allowance	(173,542)	(24,282)
Actual tax expense

XML 45 R34.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 2) - USD ($)	12 Months Ended
Income Taxes (Details 2) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets
Net operating loss carry forwards	$ 1,161,700	$ 241,690
Deferred tax asset before valuation allowance	223,831	50,289
Deferred tax assets
Valuation allowance
Beginning balance	(50,289)	(26,007)
Changes during the period	(173,542)	(24,282)
Ending balance	$ (223,831)	$ (50,289)

XML 46 R35.htm IDEA: XBRL DOCUMENT

Income Taxes (Detail Textuals)	12 Months Ended
Income Taxes (Detail Textuals)	Dec. 31, 2016 USD ($)
Income Tax Disclosure [Abstract]
Federal taxing authorities examination period	5 years
Statutory income tax rate in Singapore	17.00%
Statutory income tax rate in the United States	34.00%
Net operating loss carry forwards	$ 1,161,700

XML 47 R36.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017	$ 790,578
2018	457,567
2019	110,592
Total	$ 1,358,737

XML 48 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Detail Textuals) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expenses	$ 845,684	$ 561,167

XML 49 R38.htm IDEA: XBRL DOCUMENT

Subsequent Events (Detail Textuals) - Subsequent Event	Jun. 05, 2017 USD ($)	Feb. 14, 2017 USD ($) Agreement shares	Feb. 14, 2017 SGD Agreement shares
Smile Central
Subsequent Event [Line Items]
Intra-company loans		$ 600,000
Ownership percent	100.00%
Majority Shareholders \| Smile Central
Subsequent Event [Line Items]
Number of shares acquired with exchange of outstanding share capital \| shares		3,000,000	3,000,000
Majority Shareholders \| Targeted Solutions Global Limited
Subsequent Event [Line Items]
Amount received from TSG under Stock Purchase Agreement	$ 200,000
Lease agreement
Subsequent Event [Line Items]
Number of lease agreements \| Agreement		4	4
Amount of lease agreements for property, plant, and equipment		$ 655,494	SGD 948,616
Share Exchange Agreement ("Share Exchange Agreement") \| Eminent Healthcare Pte. Ltd \| Liew Min Hin
Subsequent Event [Line Items]
Ownership percent	100.00%

Nevada		8052		37-1793037
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Number)		(IRS Employer Identification Number)

		Page

PART I

Item 1.	Description of Business.		3
Item 1A.	Risk Factors.		9
Item 1B.	Unresolved Staff Comments.		17
Item 2	Description of Property.		18
Item 3.	Legal Proceedings.		18
Item 4.	Mine Safety Disclosures.		18

PART II

Item 5.	Market for Common Equity and Related Stockholder Matters.		19
Item 6.	Selected Financial Data.		20
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.		20
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.		23
Item 8.	Financial Statements and Supplementary Data.		24
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.		34
Item 9A.	Controls and Procedures		34
Item 9B.	Other Information.		35

PART III

Item 10	Directors, Executive Officers, Promoters and Control Persons of the Company.		36
Item 11.	Executive Compensation.		37
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.		38
Item 13.	Certain Relationships and Related Transactions, and Director Independence.		39
Item 14.	Principal Accounting Fees and Services.		39

PART IV

Item 15.	Exhibits		40

Signatures

·	Invisible braces for the young and for working adults.
·	Dental implants to rehabilitate functionality.

·	Laser Teeth Whitening
·	Aesthetic Implants and Implant Maintenance
·	Laser Surgery - used to perform soft-tissue surgery, including removing tumors and lesions from the soft tissues of the mouth, as well as tooth cleaning and plaque removal
·	Oral and Maxillofacial surgery - the treatment of many diseases, injuries and defects in the head, neck, face, jaws and the hard and soft tissues of the Oral (mouth) and Maxillofacial (jaws and face) region.

	·	21 hospitals and medical centres and medical organizations in Singapore have obtained the Joint Commission International (JCI) accreditation.

	·	Singapore's blood supply ranks among the safest in the world. Blood Services Group HSA (previously known as Singapore's Centre for Transfusion) was appointed a World Health Organization (WHO) Collaborating Blood Centre for Transfusion Medicine for the Western Pacific Region in 1992.

Clinic	Rental per mth		Tenancy Period
Aljunied	$	7,000	Aug 2014 – Jul 2017

Aljunied – Dental Lab	$	2,000	May 2015 – May 2017

Jurong	$	34,000	Sep 2015 – Sep 2018

Hougang	$	19,916	May 2015 – May 2018

HougangCentral	$	6,500	Apr 2014 – Apr 2016

SCD Centre	$	20,000	Aug 2016 – Aug 2019

Toa Payoh	$	16,000	Apr 2015 – Mar 2018

·	Successful marketing and sale of our dental services and plan;
·	Our ability to acquire or open additional dental practices and operate them profitably;
·	Our ability to develop additional services and plans to serve dentists and their patients.

·	the availability of financial resources to commence and complete the planned trial;
·	reaching agreement on acceptable terms with prospective third parties to assist in the research, the terms of which can be subject to extensive negotiation and may vary significantly;
·	obtaining approval at each clinical trial site by an independent institutional review board;
·	recruiting suitable patients to participate in a trial;
·	having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;
·	clinical trial sites deviating from trial protocol or dropping out of a trial; or
·	adding new clinical trial sites.

/s/ Accell Audit & Compliance, P.A.

Tampa, Florida

June 16, 2017

	December 31, 2016			December 31, 2015

ASSETS
Current Assets
Cash and cash equivalents	$	287,754		$	316,603
Accounts receivable		416,658			263,817
Other receivables		-			69,000
Prepaid expenses and deposits		222,084			193,723
Inventory		113,229			84,167
Total Current Assets		1,039,725			927,310
Property and equipment, net		1,037,656			993,968
TOTAL ASSETS	$	2,077,381		$	1,921,278

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable	$	633,247		$	470,073
Accrued and other payables		186,894			114,191
Due to related parties		1,150,316			1,003,296
Deferred revenue		2,454			-
Capital lease obligations - current		187,171			212,570
Total Current Liabilities		2,160,082			1,800,130
Capital lease obligations		177,083			175,343
TOTAL LIABILITIES		2,337,165			1,975,473

COMMITMENTS AND CONTINGENCIES (NOTE 9)

STOCKHOLDERS’ DEFICIT
Common stock, $0.001 par value; 500,000,000 shares authorized, 3,697,000 and 3,000,000 shares issued and outstanding, respectively		3,697			3,000
Additional paid-in capital		867,424			171,121
Accumulated deficit		(1,161,700	)		(241,690	)
Accumulated other comprehensive gain		30,795			13,374
TOTAL STOCKHOLDERS' DEFICIT		(259,784	)		(54,195	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	2,077,381		$	1,921,278

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015

DENTAL SERVICE REVENUE, NET	$	6,543,428		$	4,905,241
COST OF SERVICES		5,673,813			3,781,246
GROSS PROFIT		869,615			1,123,995

OPERATING EXPENSES
Rental		845,684			561,167
General and administrative		384,287			158,781
Professional fees		299,956			408,413
Depreciation		236,711			139,930
Staff costs		117,415			88,473
Total Operating Expenses		1,884,053			1,356,764

LOSS FROM OPERATIONS		(1,014,438	)		(232,769	)

OTHER INCOME/(EXPENSE)
Other income		102,832			149,894
Interest expense		(8,404	)		(5,833	)
		94,428			144,061

LOSS BEFORE INCOME TAXES		(920,010	)		(88,708	)
Provision for income taxes		-			-

NET LOSS	$	(920,010	)	$	(88,708	)

OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments		17,421			6,976
TOTAL COMPREHENSIVE LOSS	$	(902,589	)	$	(81,732	)

Basic and Diluted Loss per Common Share	$	0.25		$	(0.06	)
Basic and Diluted Weighted Average Common Shares Outstanding		3,647,486			1,495,371

										Accumulated
	Common Stock				Additional					Other		Total
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive Loss		Stockholders' Deficit

Balance - December 31, 2014		907,320	$	907	$	-	$	(152,982	)	$	6,398	$	(145,677	)
Adjustment on shares exchange		2,092,680		2,093		69,257		-			-		71,350
Loans forgiven by shareholder		-		-		101,864		-			-		101,864
Net loss		-		-		-		(88,708	)		-		(88,708	)
Foreign currency translation adjustments		-		-		-		-			6,976		6,976
Balance - December 31, 2015		3,000,000		3,000		171,121		(241,690	)		13,374		(54,195	)
Adjustment on shares exchange													-
Issuance of shares		697,000		697		696,303		-			-		697,000
Net loss		-		-		-		(920,010	)		-		(920,010	)
Foreign currency translation adjustments		-		-		-		-			17,421		17,421
Balance - December 31, 2016		3,697,000	$	3,697	$	867,424	$	(1,161,700	)	$	30,795	$	(259,784	)

Name		Age		Positions Held		Date of Appointment
Jiang Chun Yan		34		Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Member of the Board of Directors		June 5, 2017

Title of Class	Name and Address of beneficial owner	Amount and nature of beneficial ownership⁽¹⁾		Percent of class
Common Stock	Targeted Solutions Global Limited The Bristol Office, 2^nd Fl., 5 High Street, Westbury on Trym [Bristol, United Kingdom		3,000,000		81.14	%

Common Stock	Jiang Chun Yan ⁽²⁾ The Bristol Office, 2^nd Fl., 5 High Street, Westbury on Trym Bristol, United Kingdom		-0-		0	%

Fee Category	Year Ended December 31, 2016		Year Ended December 31, 2015

Audit Fees	$	34,500	$	21,500
Audit-Related Fees		-		-
Tax Fees		-		-
All Other Fees		-		-
Total Fees	$	34,500	$	21,500

10.1	Share Exchange Agreement, dated May 29, 2017, by and between the Medico International Inc., Eminent Healthcare Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company.

31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

32.1	Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

	MEDICO INTERNATIONAL INC.

Dated June 19, 2017	By:	/s/ Jiang Chun Yan
	Name:	Jiang Chun Yan
	Title:	Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Financial and Accounting Officer), and Director


Signatures	Title	Date

/s/ Jiang Chun Yan	Chief Executive Officer, Chief Financial Officer, and Director	June 19, 2017
Jiang Chun Yan

“Business Day”		a day (other than a Saturday) on which banks in Nevada are open for business throughout their normal business hours;

“Closing”		the closing of the transactions contemplated by this Agreement;

“Completion”		completion of acquisition of the Subsidiary Shares by the Purchasers and the return of the Medico Shares to Medico (as such term is defined below) in accordance with the terms and conditions of this Agreement;

“Encumbrance”		any mortgage, charge, pledge, lien, (otherwise than arising by statute or operation of law), equities, hypothecation or other encumbrance, priority or security interest, preemptive right deferred purchase, title retention, leasing, sale-and-repurchase or sale-and-leaseback arrangement whatsoever over or in any property, assets or rights of whatsoever nature and includes any agreement for any of the same and reference to “Encumbrances” shall be construed accordingly;

“US”		United States of America;

“United States Dollars” or “US$”		United States dollars;

	(i)	TSG shall assign and deliver the Patent to Medico;

	(ii)	TSG shall pay Two Hundred Thousand US Dollars (USD $200,000) to the Purchasers;

	(iii)	Purchasers shall transfer and deliver to TSG all of the shares of common stock of Medico owned by the Purchasers, which amount of shares shall equal Three Million (3,000,000) shares (the “Medico Shares”);

	(iv)	Medico will transfer all of the Subsidiary Shares to the Purchasers and shall allocated thirty percent (30%) to EH and seventy percent (70%) to MC; and

	(v)	Medico shall provide the Subsidiary with a Waiver and Release to forgive the Intra-Company Loan.

	(b)	The transfers described above are referred to herein as a “Transfer” and collectively as the “Transfers”. All assets, shares and property that are part of the Transfers shall be acquired by the respective recipient free from all Encumbrances together with all rights now or hereafter attaching thereto and the Subsidiary shall continue to operate in its normal course of business.

	(c)	The Share Exchange shall take place upon the terms and conditions provided for in this Agreement and in accordance with applicable law. If the Closing does not occur as set forth in Section 2.02 of this Agreement due to one Party’s failure to perform, then either of the other Parties may terminate this Agreement.

	(i)	the execution and delivery of this Agreement by each Purchaser; and

	(ii)	the sale and transfer of such respective Purchaser’s portion of the Medico Shares to TSG; and

	(i)	the execution and delivery of this Agreement by Medico; and

	(ii)	the sale and transfer of the Subsidiary Shares to Purchasers.

	(i)	the execution and delivery of this Agreement by Medico;

	(ii)	the payment of Two Hundred Thousand US Dollars to the Purchasers; and

	(iii)	the sale and assignment of the Patent to Medico.

	(a)	To maintain the books, records, accounting and financial statements of the Subsidiary and all operations related to its current business, in accordance with applicable accounting principles and practices.

	(b)	To maintain all of the legal requirements that permit the Subsidiary to operate its current business under the federal and provincial laws and regulations of Singapore and comply with all other federal and provincial laws and regulations of Singapore.

	(c)	Not to incur any debt by the Subsidiary in any event whatsoever, except with the prior written consent of the Board of Directors of Medico.

/s/ Jiang Chun Yan
Jiang Chun Yan, Chief Executive Officer/President and Chief Financial Officer